var title_f22_60_23488="Doppler ultrasound of the umbilical artery";
var content_f22_60_23488=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1086px;\">",
"  <div class=\"videoplayer\" h264=\"./images/OBGYN/87280/Doppl_US_umbil_artery_video.mp4?title=Doppler+ultrasound+of+the+umbilical+artery\" style=\"width:496px;height:384px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Doppler ultrasound of the umbilical artery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 296px; height: 380px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (Upper panel) Color flow depiction of umbilical blood flow in a normal pregnancy. The cursor line representing the Doppler ultrasound beam path can be seen aligned with the vascular flow axis. The two short horizontal lines indicate the Doppler interrogation site in the umbilical arterial flow.",
"    <br/>",
"    (Lower panel) Doppler waveforms: the vertical axis shows the scale of the flow velocity. Note the low wall filter (40 Hz) depicted in small print in the upper right area of the image panel. The waveforms show prominent end-diastolic flow reflecting low impedance in the fetoplacental arterial circulation downstream from the measurement point.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dev Maulik, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_60_23488=[""].join("\n");
var outline_f22_60_23488=null;
var title_f22_60_23489="Buckle fracture tibia";
var content_f22_60_23489=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F60438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F60438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 514px\">",
"   <div class=\"ttl\">",
"    Buckle fracture of the tibia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 494px; height: 448px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Distal tibial buckle fracture in a 14-month-old toddler with a limp.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eglal Shalaby-Rana, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_60_23489=[""].join("\n");
var outline_f22_60_23489=null;
var title_f22_60_23490="Technetium Tc-99m labeled red blood cells: Drug information";
var content_f22_60_23490=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Technetium Tc-99m labeled red blood cells: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?36/50/37666?source=see_link\">",
"    see \"Technetium Tc-99m labeled red blood cells: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13206541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      UltraTag&reg; RBC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13206545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Radiopharmaceutical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F13206556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Gated equilibrium radionuclide ventriculography:",
"     </b>",
"     I.V.: 15-30 mCi (555-1110 MBq)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      GI bleeding:",
"     </b>",
"     I.V.: 20-30 mCi (750-1110 MBq)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hepatic blood pool imaging:",
"     </b>",
"     I.V.: 20-25 mCi (750-925 MBq)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Splenic imaging using heat-damaged technetium Tc 99m RBCs:",
"     </b>",
"     I.V.: 1-3 mCi (40-110 MBq)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F13206557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Gated equilibrium radionuclide ventriculography:",
"     </b>",
"     I.V.: 0.2-0.4 mCi/kg (7-15 MBq/kg); minimum dose: 2-4 mCi (70-150 MBq)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      GI bleeding:",
"     </b>",
"     I.V.: 0.3-0.4 mCi/kg (10-15 MBq/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hepatic blood pool imaging:",
"     </b>",
"     I.V.: 0.2-0.3 mCi/kg (7-11 MBq/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Splenic imaging using heat-damaged technetium Tc 99m RBCs:",
"     </b>",
"     I.V.: 0.02-0.04 mCi/kg (0.7-1.5 MBq/kg)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13206546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pool imaging agent (including cardiac first pass and gated equilibrium imaging); detection of active lower GI bleeding; evaluation of suspected hemangiomas in liver; specific imaging of spleen to determine presence of functioning tissue",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13255275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13206559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use only  under supervision of individuals who have received training in the handling of radioactive materials and who are authorized by the applicable regulatory authority.",
"     <b>",
"      Note:",
"     </b>",
"     Contents of kit are not radioactive; however, adequate shielding is required after addition of radioactive material.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13206558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13206561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have not been conducted. There are no adequate and well-controlled studies in pregnant women. Radiopharmaceuticals have the potential to cause fetal harm. Use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13206562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13206563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     One report states that 0.02% to 0.03% is excreted into breast milk, resulting in &lt;100 mrem (1 mSv) effective dose to the infant (Stabin, 2000); therefore, interruption of breast-feeding is not necessary (U.S. Nuclear Regulatory Commission, 1977).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ford PV, Bartold SP, Fink-Bennett DM, et al, \"Procedure Guideline for Gastrointestinal Bleeding and Meckel&rsquo;s Diverticulum Scintigraphy. Society of Nuclear Medicine,\"",
"      <i>",
"       J Nucl Med",
"      </i>",
"      , 1999, 40(7):1226-32. Available at file://interactive.snm.org/docs/pg_ch09_0403.pdf. Last accessed August 30, 2011.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/60/23490/abstract-text/10405149/pubmed\" id=\"10405149\" target=\"_blank\">",
"        10405149",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Royal HD, Brown ML, Drum DE, et al, \"Society of Nuclear Medicine Procedure Guideline for Hepatic and Splenic Imaging,\" 2003.  Available at file://interactive.snm.org/docs/pg_ch10_0403.pdf. Last accessed August 30, 2011.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scheiner J, Sinusas A, Wittry MD, et al, \"Society of Nuclear Medicine Procedure Guideline for Gated Equilibrium Radionuclide Ventriculography,\" 2002. Available at file://interactive.snm.org/docs/pg_ch01_0403.pdf. Last accessed August 30, 2011.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stabin MG and Breitz HB, \"Breast Milk Excretion of Radiopharmaceuticals: Mechanisms, Findings, and Radiation Dosimetry,\"",
"      <i>",
"       J Nucl Med",
"      </i>",
"      , 2000, 41(5):863-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/60/23490/abstract-text/10809203/pubmed\" id=\"10809203\" target=\"_blank\">",
"        10809203",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      U.S. Nuclear Regulatory Commission, \"Regulatory Guide 8.39. Release of Patients Administered Radioactive Materials,\" 1977.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16813 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-FDF33D9AD5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_60_23490=[""].join("\n");
var outline_f22_60_23490=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206541\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206545\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206556\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206557\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206546\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13255275\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206559\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206558\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206561\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206562\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206563\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16813\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16813|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/50/37666?source=related_link\">",
"      Technetium Tc-99m labeled red blood cells: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_60_23491="Calcium and vitamin D for bone health";
var content_f22_60_23491=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?22/60/23491/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/60/23491/contributors\" id=\"au5515\">",
"       Harold N Rosen, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?22/60/23491/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/60/23491/contributors\" id=\"se178\">",
"       Clifford J Rosen, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?22/60/23491/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/60/23491/contributors\" id=\"de1470\">",
"       Jean E Mulder, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?22/60/23491?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      CALCIUM AND VITAMIN D OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Osteoporosis is a common bone disorder that causes a progressive loss in bone density and mass. As a result, bones become thin, weakened, and easily fractured. It is estimated that more than 1.3 million osteoporosis",
"     <strong>",
"      -",
"     </strong>",
"     associated (or \"osteoporotic\") fractures occur every year in the United States, primarily of bone within the spine (the vertebrae), the hip, and the forearm near the wrist. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/29/1491?source=see_link\">",
"      \"Patient information: Bone density testing (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     A number of treatments can help to prevent loss of bone and treat low bone mass. However, the first step in preventing or treating osteoporosis is to consume foods and drinks that provide calcium, a mineral essential for bone strength, and vitamin D, which aids in calcium breakdown and absorption. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/49/25366?source=see_link\">",
"      \"Patient information: Osteoporosis prevention and treatment (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      CALCIUM AND VITAMIN D BENEFITS",
"     </span>",
"    </p>",
"    <p>",
"     Good nutrition is important at all ages to keep the bones healthy.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Taking calcium reduces bone loss and decreases the risk of fracturing the vertebrae (the bones that surround the spinal cord).",
"      </li>",
"      <li>",
"       Consuming calcium during childhood (eg, in milk) can lead to higher bone mass in adulthood. This increase in bone density can reduce the risk of fractures later in life.",
"      </li>",
"      <li>",
"       Calcium also has benefits in other body systems by reducing blood pressure and cholesterol levels.",
"      </li>",
"      <li>",
"       Calcium and vitamin D supplements have been shown to help prevent tooth loss in older adults.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      RECOMMENDATIONS FOR CALCIUM",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      General recommendations",
"     </span>",
"     &nbsp;&mdash;&nbsp;Premenopausal women and men should consume at least 1000 mg while postmenopausal women should consume 1200 mg (total diet plus supplement). You should not consume more than 2000 mg of calcium per day due to the risk of side effects.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h3\">",
"      Calcium in the diet",
"     </span>",
"     &nbsp;&mdash;&nbsp;The primary sources of calcium in the diet include milk and other dairy products, such as hard cheese, cottage cheese, or yogurt, as well as green vegetables, such as kale and broccoli (",
"     <a class=\"graphic graphic_table graphicRef67824 \" href=\"UTD.htm?28/58/29611\">",
"      table 1",
"     </a>",
"     ). Cottage cheese and ice cream contain approximately 150 mg of calcium per 4 oz (120 mL). Other foods, such as dark green vegetables, some nuts, breads, and cereals, supply an average of 200 mg of calcium daily. Some cereals, soy products, and fruit juices are fortified with up to 1000 mg of calcium per serving.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Calcium supplements",
"     </span>",
"     &nbsp;&mdash;&nbsp;The body is able to absorb calcium contained in supplements as well as from dietary sources. If it is not possible to get enough calcium from dietary sources, consult a healthcare provider to determine the best type, dose, and timing of calcium supplements. The table shows the calcium and vitamin D content in commonly available supplements (",
"     <a class=\"graphic graphic_table graphicRef70454 \" href=\"UTD.htm?36/37/37468\">",
"      table 2",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Calcium carbonate is effective and is the least expensive form of calcium. It is best absorbed with a low-iron meal (such as breakfast). Calcium carbonate is not absorbed well in people who also take a specific medication for gastroesophageal reflux (called a proton pump inhibitor or H2 blocker). (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=see_link\">",
"        \"Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Calcium citrate is absorbed best when it is taken on an empty stomach.",
"      </li>",
"      <li>",
"       Many natural calcium carbonate preparations such as oyster shells or bone meal contain some lead. The low lead levels in calcium supplements are unlikely to be a health risk because calcium blocks lead absorption.",
"      </li>",
"      <li>",
"       Calcium supplements should be taken in divided doses (eg, in the morning and evening). Doses above 500 mg are not absorbed as well as smaller doses.",
"      </li>",
"      <li>",
"       Calcium supplements do not replace other osteoporosis treatments. Calcium is less effective than other treatments, including hormone replacement, bisphosphonates (eg, risedronate [Actonel&reg;] and alendronate [Fosamax&reg;]), and raloxifene (Evista&reg;). Calcium has additive benefits when used along with other treatments. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?24/49/25366?source=see_link\">",
"        \"Patient information: Osteoporosis prevention and treatment (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Underlying gastrointestinal diseases",
"     </span>",
"     &nbsp;&mdash;&nbsp;Patients who do not adequately absorb nutrients from the gastrointestinal tract (due to malabsorption) may require more than 1000 mg of calcium per day. In such cases, a healthcare provider can help to determine the optimal dose of calcium.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;All medications should be discussed with a healthcare provider to ensure that possible interactions with calcium are identified. Certain medications change the amount of calcium that is absorbed",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     excreted. As an example, loop diuretics (eg, furosemide, Lasix&reg;) increase the amount of calcium excreted in the urine.",
"    </p>",
"    <p>",
"     On the other hand, thiazide diuretics (eg, hydrochlorothiazide, HCTZ) can reduce levels of calcium in the urine, potentially reducing the risk of bone loss and kidney stones (see",
"     <a class=\"local\" href=\"#H10\">",
"      'Kidney stones'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Side effects of calcium",
"     </span>",
"     &nbsp;&mdash;&nbsp;Calcium is usually easily tolerated when it is taken in divided doses several times per day. Some people experience side effects related to calcium, including constipation and indigestion. Calcium supplements interfere with the absorption of iron and thyroid hormone and, therefore, these medications should be taken at different times.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Kidney stones",
"     </span>",
"     &nbsp;&mdash;&nbsp;There is little evidence that consuming large amounts of calcium (from foods and drinks) increases the risk of kidney stones, or that consuming small amounts of calcium decreases the risk. In fact, avoiding dairy products is likely to increase the risk of kidney stones.",
"    </p>",
"    <p>",
"     However, use of calcium supplements may increase the risk of kidney stones in susceptible individuals by raising the level of calcium in the urine. This is particularly true if the supplement is taken between meals or at bedtime. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/53/28499?source=see_link\">",
"      \"Patient information: Kidney stones in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      IMPORTANCE OF VITAMIN D",
"     </span>",
"    </p>",
"    <p>",
"     Vitamin D decreases bone loss and lowers the risk of fracture, especially in older men and women. Along with calcium, vitamin D also helps to prevent and treat osteoporosis. To absorb calcium efficiently, an adequate amount of vitamin D must be present.",
"    </p>",
"    <p>",
"     Vitamin D is normally made in the skin after exposure to sunlight. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/62/15331?source=see_link\">",
"      \"Patient information: Vitamin D deficiency (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Recommendations for vitamin D",
"     </span>",
"     &nbsp;&mdash;&nbsp;The current recommendation is that men over 70 years and postmenopausal women consume at least 800 international units of vitamin D per day. Lower levels of vitamin D are not as effective while high doses can be toxic, especially if taken for long periods of time. Although the optimal intake has not been clearly established in premenopausal women or in younger men with osteoporosis, 600 international units of vitamin D daily is generally suggested.",
"    </p>",
"    <p>",
"     Vitamin D is available as an individual supplement and is included in most multivitamins and some calcium supplements&nbsp;(",
"     <a class=\"graphic graphic_table graphicRef70454 \" href=\"UTD.htm?36/37/37468\">",
"      table 2",
"     </a>",
"     ). Milk is the best dietary source of vitamin D, with approximately 100 international units per cup (",
"     <a class=\"graphic graphic_table graphicRef77982 \" href=\"UTD.htm?7/12/7372\">",
"      table 3",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H367083\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H367090\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/12/36034?source=see_link\">",
"      Patient information: Calcium and vitamin D for bone health (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/58/35746?source=see_link\">",
"      Patient information: Osteoporosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/45/10962?source=see_link\">",
"      Patient information: Vitamin D deficiency (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/35/11827?source=see_link\">",
"      Patient information: Diet and health (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/13/7379?source=see_link\">",
"      Patient information: Health and nutrition for women who breastfeed (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/7/8307?source=see_link\">",
"      Patient information: Ankylosing spondylitis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/6/2147?source=see_link\">",
"      Patient information: Primary hyperparathyroidism (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/20/7491?source=see_link\">",
"      Patient information: Common wrist injuries (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/5/3155?source=see_link\">",
"      Patient information: Finger fracture (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/26/39330?source=see_link\">",
"      Patient information: Clavicle fracture (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/33/14867?source=see_link\">",
"      Patient information: Hip fracture (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/53/41810?source=see_link\">",
"      Patient information: Rib fractures in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/33/12819?source=see_link\">",
"      Patient information: Shinbone fracture (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/63/27635?source=see_link\">",
"      Patient information: Vertebral compression fracture (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/25/40338?source=see_link\">",
"      Patient information: Ankle fracture (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/6/5219?source=see_link\">",
"      Patient information: Boxer&rsquo;s fracture (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/0/15363?source=see_link\">",
"      Patient information: Neck fracture (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/21/5459?source=see_link\">",
"      Patient information: Pelvic fracture (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/22/355?source=see_link\">",
"      Patient information: Toe fracture (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/38/40546?source=see_link\">",
"      Patient information: Vitamin supplements (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/41/6803?source=see_link\">",
"      Patient information: Medicines for osteoporosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/57/13202?source=see_link\">",
"      Patient information: Vitamin D for babies and children (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/23/16754?source=see_link\">",
"      Patient information: Monoclonal gammopathy of undetermined significance (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/59/12211?source=see_link\">",
"      Patient information: Paget disease of bone (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H367115\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/29/1491?source=see_link\">",
"      Patient information: Bone density testing (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/49/25366?source=see_link\">",
"      Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=see_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/53/28499?source=see_link\">",
"      Patient information: Kidney stones in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/62/15331?source=see_link\">",
"      Patient information: Vitamin D deficiency (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H367127\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43173?source=see_link\">",
"      Calcitonin in the prevention and treatment of osteoporosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12170?source=see_link\">",
"      Calcium and vitamin D supplementation in osteoporosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/18/38184?source=see_link\">",
"      Causes of vitamin D deficiency and resistance",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42679?source=see_link\">",
"      Diet in the treatment and prevention of hypertension",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/25/6553?source=see_link\">",
"      Epidemiology and etiology of premenopausal osteoporosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42553?source=see_link\">",
"      Evaluation and treatment of premenopausal osteoporosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=see_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Osteoporosis and Related Bone Diseases National Resource Center (ORBD-NRC)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.osteo.org/\">",
"      www.osteo.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Osteoporosis Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nof.org/\">",
"      www.nof.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Osteoporosis Society of Canada",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.osteoporosis.ca/\">",
"      www.osteoporosis.ca/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Hormone Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.hormone.org/public/osteoporosis.cfm\">",
"      www.hormone.org/public/osteoporosis.cfm",
"     </a>",
"     , available in English and Spanish)",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?22/60/23491/abstract/1-7\">",
"      1-7",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 17, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?22/60/23491?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23491/abstract/1\">",
"      NIH Consensus conference. Optimal calcium intake. NIH Consensus Development Panel on Optimal Calcium Intake. JAMA 1994; 272:1942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23491/abstract/2\">",
"      Aloia JF, Vaswani A, Yeh JK, et al. Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss. Ann Intern Med 1994; 120:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23491/abstract/3\">",
"      Cook JD, Dassenko SA, Whittaker P. Calcium supplementation: effect on iron absorption. Am J Clin Nutr 1991; 53:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23491/abstract/4\">",
"      Curhan GC, Willett WC, Speizer FE, et al. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med 1997; 126:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23491/abstract/5\">",
"      Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23491/abstract/6\">",
"      Ross EA, Szabo NJ, Tebbett IR. Lead content of calcium supplements. JAMA 2000; 284:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23491/abstract/7\">",
"      Heaney RP. Lead in calcium supplements: cause for alarm or celebration? JAMA 2000; 284:1432.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f22_60_23491=[""].join("\n");
var outline_f22_60_23491=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           CALCIUM AND VITAMIN D OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           CALCIUM AND VITAMIN D BENEFITS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           RECOMMENDATIONS FOR CALCIUM",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           IMPORTANCE OF VITAMIN D",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?28/58/29611\" title=\"table 1\">",
"           Foods with calcium PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?36/37/37468\" title=\"table 2\">",
"           Calcium supplements PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?7/12/7372\" title=\"table 3\">",
"           Sources of vitamin D PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f22_60_23492="Travoprost and timolol: Patient drug information";
var content_f22_60_23492=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Travoprost and timolol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/31/14838?source=see_link\">",
"     see \"Travoprost and timolol: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5094947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      DuoTrav&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691860",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat glaucoma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower high eye pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703067",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to travoprost, timolol, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703318",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Asthma, very weak heart, or slow heartbeat without a working pacemaker.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may hide the signs of low blood sugar. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697236",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an eye infection, eye surgery, or eye injury, start a new bottle of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698504",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your eye pressure checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye color may change with use. This drug may raise the brown pigment. Dark eyelashes and skin around the eye may also happen. These changes may be long-lasting.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12012 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-202.43.93.2-04D01F2D42-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_60_23492=[""].join("\n");
var outline_f22_60_23492=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5094947\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016180\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016179\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016184\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016185\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016187\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016182\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016183\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016188\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016189\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/31/14838?source=related_link\">",
"      Travoprost and timolol: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_60_23493="Examination of finger DIP joint flexion";
var content_f22_60_23493=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73661%7EEM%2F58818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73661%7EEM%2F58818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Examination of finger DIP joint flexion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 312px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Flexion of the distal interphalangeal (DIP) joint is evaluated independently of other finger movements.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Examination of finger DIP joint extension",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 309px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Distal interphalangeal (DIP) joint extension should be evaluated independently of other finger movements, as depicted in the photograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_60_23493=[""].join("\n");
var outline_f22_60_23493=null;
var title_f22_60_23494="Infil UC microcyst variant";
var content_f22_60_23494=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F56532&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F56532&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 526px\">",
"   <div class=\"ttl\">",
"    Infiltrating urothelial carcinoma, microcystic variant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 506px; height: 192px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) At low power (20x) the microcystic variant of infiltrating urothelial carcinoma tumor may show a striking cystic pattern. B) At high power (40x) the cysts contain necrotic material or pink secretions. The cyst lining may be flattened or absent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cristina Magi-Galluzzi, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_60_23494=[""].join("\n");
var outline_f22_60_23494=null;
var title_f22_60_23495="Lisinopril and hydrochlorothiazide: Drug information";
var content_f22_60_23495=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lisinopril and hydrochlorothiazide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/37/30294?source=see_link\">",
"    see \"Lisinopril and hydrochlorothiazide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F189274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Prinzide&reg;;",
"     </li>",
"     <li>",
"      Zestoretic&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F189275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Lisinopril&reg;/Hctz;",
"     </li>",
"     <li>",
"      Mylan-Lisinopril/Hctz;",
"     </li>",
"     <li>",
"      Novo-Lisinopril/Hctz;",
"     </li>",
"     <li>",
"      Prinzide&reg;;",
"     </li>",
"     <li>",
"      Sandoz-Lisinopril/Hctz;",
"     </li>",
"     <li>",
"      Teva-Lisinopril/Hctz (Type P);",
"     </li>",
"     <li>",
"      Teva-Lisinopril/Hctz (Type Z);",
"     </li>",
"     <li>",
"      Zestoretic&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F189291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin-Converting Enzyme (ACE) Inhibitor;",
"     </li>",
"     <li>",
"      Diuretic, Thiazide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F189278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial: Lisinopril 10 mg/hydrochlorothiazide 12.5 mg or lisinopril 20 mg/hydrochlorothiazide 12.5 mg with further increases of either or both components could depend on clinical response. Doses &gt;80 mg/day lisinopril or &gt;50 mg/day hydrochlorothiazide are not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F189279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F189280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage adjustments should be made with caution. Usual regimens of therapy need not be adjusted as long as patient's Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;30 mL/minute. In patients with more severe renal impairment, loop diuretics are preferred.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16265645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F189263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral: 10/12.5: Lisinopril 10 mg and hydrochlorothiazide 12.5 mg; 20/12.5: Lisinopril 20 mg and hydrochlorothiazide 12.5 mg; 20/25: Lisinopril 20 mg and hydrochlorothiazide 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Prinzide&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     10/12.5: Lisinopril 10 mg and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;text-align:justify;\">",
"     20/12.5: Lisinopril 20 mg and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zestoretic&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     10/12.5: Lisinopril 10 mg and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     20/12.5: Lisinopril 20 mg and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     20/25: Lisinopril 20 mg and hydrochlorothiazide 25 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F189252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F189265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F189289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F189268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Hypersensitivity to lisinopril, any other ACE inhibitor, hydrochlorothiazide, sulfonamide-derived drugs, or any component of the formulation; angioedema related to previous treatment with an ACE inhibitor; patients with idiopathic or hereditary angioedema; concomitant use with aliskiren in patients with diabetes mellitus; anuria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F189255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angioedema: At any time during treatment (especially following first dose), angioedema may occur rarely with ACE inhibitors; it may involve the head and neck (potentially compromising airway) or the intestine (presenting with abdominal pain). African-Americans may be at an increased risk. Prolonged frequent monitoring may be required especially if tongue, glottis, or larynx are involved as they are associated with airway obstruction. Patients with a history of airway surgery may have a higher risk of airway obstruction. Aggressive early and appropriate management is critical. Use in patients with idiopathic or hereditary angioedema or previous angioedema associated with ACE inhibitor therapy is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cholestatic jaundice: A rare toxicity associated with ACE inhibitors includes cholestatic jaundice, which may progress to fulminant hepatic necrosis; discontinue if marked elevation of hepatic transaminases or jaundice occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cough: An ACE inhibitor cough is a dry, hacking, nonproductive one that usually occurs within the first few months of treatment and should generally resolve within 1-4 weeks after discontinuation of the ACE inhibitor. Other causes of cough should be considered (eg, pulmonary congestion in patients with heart failure) and excluded prior to discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte disturbances: Hyperkalemia may occur with ACE inhibitors; risk factors include renal dysfunction, diabetes mellitus, and concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts. Use cautiously, if at all, with these agents and monitor potassium closely. Thiazide diuretics may cause hypokalemia, hypochloremic alkalosis, hypomagnesemia, and hyponatremia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Anaphylactic/anaphylactoid reactions can occur with ACE inhibitors. Severe anaphylactoid reactions may be seen during hemodialysis (eg, CVVHD) with high-flux dialysis membranes (eg, AN69), and rarely, during low density lipoprotein apheresis with dextran sulfate cellulose. Rare cases of anaphylactoid reactions have been reported in patients undergoing sensitization treatment with hymenoptera (bee, wasp) venom while receiving ACE inhibitors. Hypersensitivity reactions may also occur with hydrochlorothiazide; risk is increased in patients with a history of allergy or bronchial asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can occur with ACE inhibitors (usually with the first several doses); effects are most often observed in volume-depleted patients; correct volume depletion prior to initiation; close monitoring of patient is required especially with initial dosing and dosing increases; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Although dose reduction may be necessary, hypotension is not a reason for discontinuation of future ACE inhibitor use especially in patients with heart failure where a reduction in systolic blood pressure is a desirable observation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neutropenia/agranulocytosis: Another ACE Inhibitor, captopril, has been associated with rare cases of agranulocytosis, neutropenia, or leukopenia with myeloid hypoplasia. Patients with renal impairment are at high risk of developing neutropenia. Patients with both renal impairment and collagen vascular disease (eg, systemic lupus erythematosus) are at an even higher risk of developing neutropenia. Periodically monitor CBC with differential in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Hydrochlorothiazide may cause acute transient myopia and acute angle-closure glaucoma, typically occurring within hours to weeks following initiation; discontinue therapy immediately in patients with acute decreases in visual acuity or ocular pain. Risk factors may include a history of sulfonamide or penicillin allergy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Photosensitization may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfa allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic stenosis: Use with caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Initiation of therapy in patients with ischemic heart disease or cerebrovascular disease warrants close observation due to the potential consequences posed by falling blood pressure (eg, MI, stroke). Fluid replacement, if needed, may restore blood pressure; therapy may then be resumed. Discontinue therapy in patients whose hypotension recurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Collagen vascular disease: Use lisinopril with caution in patients with collagen vascular disease especially with concomitant renal impairment; may be at increased risk for hematologic toxicity. Hydrochlorothiazide can cause systemic lupus erythematosus (SLE) exacerbation or activation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use hydrochlorothiazide with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated by hydrochlorothiazide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use caution in patients with severe hepatic impairment; in cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypercalcemia: Thiazide diuretics may decrease renal calcium excretion; consider avoiding use in patients with hypercalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercholesterolemia: Use with caution in patients with moderate or high cholesterol concentrations; increased cholesterol and triglyceride levels have been reported with thiazides.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Parathyroid disease: Thiazide diuretics reduce calcium excretion; pathologic changes in the parathyroid glands with hypercalcemia and hypophosphatemia have been observed with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal artery stenosis: Use lisinopril with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use lisinopril with caution in pre-existing renal insufficiency; dosage adjustment may be needed. Avoid rapid dosage escalation which may lead to further renal impairment. Avoid hydrochlorothiazide in severe renal disease (ineffective). Contraindicated in anuric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin receptor blockers (ARBs) and renin inhibitors: Concomitant use of an ARB or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgery: Use with caution before, during, or immediately after major surgery. Cardiopulmonary bypass, intraoperative blood loss or vasodilating anesthesia increases endogenous renin release. Use of ACE inhibitors perioperatively will blunt angiotensin II formation and may result in hypotension.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F189259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Thiazide Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of ACE Inhibitors. Aliskiren may enhance the hypotensive effect of ACE Inhibitors. Aliskiren may enhance the nephrotoxic effect of ACE Inhibitors. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of ACE Inhibitors. Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprotinin: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: ACE Inhibitors may enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benazepril: Hydrochlorothiazide may enhance the hypotensive effect of Benazepril. Hydrochlorothiazide may enhance the nephrotoxic effect of Benazepril. Benazepril may decrease the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: Thiazide Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of ACE Inhibitors. Canagliflozin may enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): ACE Inhibitors may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DPP-IV Inhibitors: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ferric Gluconate: ACE Inhibitors may enhance the adverse/toxic effect of Ferric Gluconate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gold Sodium Thiomalate: ACE Inhibitors may enhance the adverse/toxic effect of Gold Sodium Thiomalate. An increased risk of nitritoid reactions has been appreciated.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Icatibant: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Dextran Complex: ACE Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions.  Management: Follow iron dextran recommendations closely regarding both having resuscitation equipment and trained personnel on-hand prior to iron dextran administration and the use of a test dose prior to the first therapeutic dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of ACE Inhibitors. Management: Administer angiotensin-converting enzyme inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Thiazide Diuretics may decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: ACE Inhibitors may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor.  Monitor patient response to lithium closely following addition or discontinuation of concurrent ACE inhibitor treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Loop Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: ACE Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: ACE Inhibitors may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ACEIs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: May enhance the hypotensive effect of Lisinopril.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valsartan: Hydrochlorothiazide may enhance the hypotensive effect of Valsartan. Valsartan may increase the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Thiazide Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F189260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F189271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F189282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F1623913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual monographs.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F189270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Lisinopril-Hydrochlorothiazide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-12.5 mg (100): $110.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-12.5 mg (100): $119.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-25 mg (100): $121.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Zestoretic Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-12.5 mg (100): $175.33",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-12.5 mg (100): $189.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-25 mg (100): $192.07",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6179709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure; BUN, serum creatinine, and electrolytes; if patient has collagen vascular disease and/or renal impairment, periodically monitor CBC with differential",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F189272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acercomp (DE);",
"     </li>",
"     <li>",
"      Acerdil D (CN, PY);",
"     </li>",
"     <li>",
"      Carace 20 (GB);",
"     </li>",
"     <li>",
"      Carace Plus (GB, IE);",
"     </li>",
"     <li>",
"      Cipril - H (IN);",
"     </li>",
"     <li>",
"      Coric Plus (DE);",
"     </li>",
"     <li>",
"      Lisiletic (VE);",
"     </li>",
"     <li>",
"      Lisipril (CO);",
"     </li>",
"     <li>",
"      Prinzide (AT, BG, BR, CH, FR, GR, IT, MX, NZ);",
"     </li>",
"     <li>",
"      Tensolisin D (DO, HN);",
"     </li>",
"     <li>",
"      Zestoretic (AE, AR, BB, BE, BF, BH, BJ, BM, BR, BS, BZ, CH, CI, CR, CY, DK, DO, EG, ES, ET, GB, GH, GM, GN, GR, GT, GY, HK, HN, ID, IE, IL, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MX, NE, NG, NI, NL, NO, OM, PA, PE, PH, PK, PT, QA, SA, SC, SD, SE, SL, SN, SR, SV, SY, TN, TR, TT, TZ, UG, YE, ZA, ZM, ZW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F189267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chase MP, Fiarman GS, Scholz FJ, et al, &ldquo;Angioedema of the Small Bowel Due to an Angiotensin-Converting Enzyme Inhibitor,&rdquo;",
"      <i>",
"       J Clin Gastroenterol",
"      </i>",
"      , 2000, 31(3):254-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/60/23495/abstract-text/11034011/pubmed\" id=\"11034011\" target=\"_blank\">",
"        11034011",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/60/23495/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaplan NM and Sever PS, &ldquo;Combination Therapy: A Key to Comprehensive Patient Care,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 1997, 10(7 Pt 2):127S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/60/23495/abstract-text/9231887/pubmed\" id=\"9231887\" target=\"_blank\">",
"        9231887",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moser M and Black HR, &ldquo;The Role of Combination Therapy in the Treatment of Hypertension,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 1998, 11(6 Pt 2):73S-8S, 95S-100S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/60/23495/abstract-text/9655566/pubmed\" id=\"9655566\" target=\"_blank\">",
"        9655566",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smoger SH and Sayed MA, &ldquo;Simultaneous Mucosal and Small Bowel Angioedema Due to Captopril,&rdquo;",
"      <i>",
"       South Med J",
"      </i>",
"      , 1998, 91(11):1060-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/60/23495/abstract-text/9824192/pubmed\" id=\"9824192\" target=\"_blank\">",
"        9824192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10196 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-46BEA4AD38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_60_23495=[""].join("\n");
var outline_f22_60_23495=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709017\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189274\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189275\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189291\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189278\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189279\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189280\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265645\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189263\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189252\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189265\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189289\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189268\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189255\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299612\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189259\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189260\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189271\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189282\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1623913\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189270\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6179709\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189272\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189267\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10196\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10196|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/37/30294?source=related_link\">",
"      Lisinopril and hydrochlorothiazide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_60_23496="Chronic bacterial prostatitis";
var content_f22_60_23496=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chronic bacterial prostatitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/60/23496/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/60/23496/contributors\">",
"     Alain Meyrier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/60/23496/contributors\">",
"     Thomas Fekete, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/60/23496/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/60/23496/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/60/23496/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/60/23496/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/60/23496/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H14689072\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prostate is subject to various inflammatory disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23496/abstract/1\">",
"     1",
"    </a>",
"    ]. One of these syndromes is chronic bacterial prostatitis, which is characterized by chronic or recurrent urogenital symptoms in the setting of documented or suspected bacterial infection of the prostate.",
"   </p>",
"   <p>",
"    Definitions of inflammatory conditions of the prostate and the syndrome of chronic bacterial prostatitis will be reviewed here. Other prostatic syndromes, including acute bacterial prostatitis and chronic",
"    <span class=\"nowrap\">",
"     prostatitis/pelvic",
"    </span>",
"    pain syndrome, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/42/4776?source=see_link\">",
"     \"Acute bacterial prostatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17720?source=see_link\">",
"     \"Chronic prostatitis/chronic pelvic pain syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14689079\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While inflammatory or irritative conditions of the prostate are common clinical presentations, they often represent distinct pathogenic processes that may benefit from different management approaches. In order to standardize definitions, improve diagnosis and treatment, and facilitate research, the United States National Institutes of Health (NIH) established an International Prostatitis Collaborative Network to devise a classification approach for prostatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23496/abstract/2\">",
"     2",
"    </a>",
"    ]. The scheme developed by this group is the currently accepted categorization of prostatitis and defines the following syndromes (",
"    <a class=\"graphic graphic_table graphicRef75162 \" href=\"UTD.htm?23/22/23916\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      I. Acute bacterial prostatitis &mdash; Acute urogenital symptoms with evidence of bacterial infection of the prostate (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/42/4776?source=see_link\">",
"       \"Acute bacterial prostatitis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      II. Chronic bacterial prostatitis &mdash; Chronic or recurrent urogenital symptoms with evidence of bacterial infection of the prostate",
"     </li>",
"     <li>",
"      IIIA. Chronic",
"      <span class=\"nowrap\">",
"       prostatitis/chronic",
"      </span>",
"      pelvic pain syndrome, inflammatory &mdash; Chronic or recurrent urogenital symptoms with evidence of inflammation, but not bacterial infection of the prostate (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17720?source=see_link\">",
"       \"Chronic prostatitis/chronic pelvic pain syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      IIIB. Chronic",
"      <span class=\"nowrap\">",
"       prostatitis/chronic",
"      </span>",
"      pelvic pain syndrome, noninflammatory &mdash; Chronic or recurrent urogenital symptoms without evidence of inflammation or bacterial infection of the prostate (formerly designated prostatodynia) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17720?source=see_link\">",
"       \"Chronic prostatitis/chronic pelvic pain syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      IV. Asymptomatic inflammatory prostatitis &mdash; Absence of urogenital symptoms with evidence of inflammation of the prostate found incidentally (eg, biopsy performed for a different purpose)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evidence of inflammation or bacterial infection is usually determined by the presence of inflammatory cells in, or bacterial growth from, expressed prostatic secretions, post-prostate massage urine, or seminal fluid. Maneuvers performed in the urology office can help refine the categorization of patients. As an example, including post-massage urine and seminal fluid for the assessment of inflammatory cells effectively doubles the number of people in the inflammatory subset (compared with using purulent prostatic secretions alone) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23496/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25602273\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of chronic bacterial prostatitis is the same as in acute infection. Entry of microorganisms into the prostate gland almost always occurs via the urethra. In most cases, bacteria migrate from the urethra or bladder through the prostatic ducts, with intraprostatic reflux of urine (",
"    <a class=\"graphic graphic_figure graphicRef54803 \" href=\"UTD.htm?19/35/20023\">",
"     figure 1",
"    </a>",
"    ). Chronic prostatitis may be a complication of acute prostatitis following inadequate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    too short treatment. (See",
"    <a class=\"local\" href=\"#H25602337\">",
"     'Risk factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14689086\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall, prostatitis is a very common presentation in the clinical setting and tends to occur in young and middle-aged men. In a study of 58,955 ambulatory visits to clinicians by men over the age of 18 years reported to the United States National Ambulatory Medical Care Surveys from 1990 to 1994, 5 percent listed genitourinary tract symptoms as a reason for the visit [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23496/abstract/4\">",
"     4",
"    </a>",
"    ]. Extrapolation of the data estimated that the diagnosis of prostatitis was associated with two million visits annually. However, actual bacterial infections of the prostate account for a minority of these cases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23496/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective study of 409 men with prostatitis syndromes, bacterial cultures of prostatic fluid were positive only in 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23496/abstract/5\">",
"     5",
"    </a>",
"    ]. The observed prevalence of bacterial prostatitis may be underestimated, as most studies infrequently evaluate for atypical organisms, such as Ureaplasma urealyticum, which in the above study was cultured in 20 percent of prostatic fluid samples. However, the role of atypical bacteria, like Ureaplasma in genitourinary infections, is not fully defined since it can be isolated from asymptomatic men as well [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23496/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25602337\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk factors for the development of chronic bacterial prostatitis have not been clearly defined. Chronic bacterial infection of the prostate can develop following an episode of acute prostatitis. In a retrospective review of 480 patients with acute prostatitis, the 49 men (10 percent) who developed chronic infection were more likely to have a history of prior manipulation of the urinary tract, voiding symptoms, diabetes, and smoking, and on average had higher prostate volumes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23496/abstract/7\">",
"     7",
"    </a>",
"    ]. Furthermore, men who had been treated for acute prostatitis, but did not develop chronic prostatic symptoms, had received a longer treatment duration compared with men who developed chronic prostatic infection (average 36.5 versus 27.5 days). However, it is unknown whether these factors contribute independently to the development of chronic infection.",
"   </p>",
"   <p>",
"    The presence of prostate stones may also contribute to the persistence of infection. In one study of men with chronic bacterial prostatitis, patients with prostate stones were more likely to experience relapse following antimicrobial therapy than patients without stones [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23496/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Otherwise, the risk factors for chronic infection appear to be similar to those observed for acute infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/42/4776?source=see_link&amp;anchor=H29437419#H29437419\">",
"     \"Acute bacterial prostatitis\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14689240\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gram-negative rods are the most common etiologic agents, with Escherichia coli causing approximately 75 to 80 percent of episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23496/abstract/9\">",
"     9",
"    </a>",
"    ]. Enterococcus faecalis, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and other gram-negative bacilli are the next most commonly reported organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23496/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Staphylococcus aureus and streptococcal species are occasional pathogens. The isolation of other gram-positive organisms, such as coagulase negative staphylococci and corynebacteria from prostatic fluid, is of uncertain clinical significance as illustrated by studies in which isolation of these organisms was neither associated with inflammatory cells in prostatic secretions nor reproducible even in the absence of antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23496/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fastidious sexually transmitted organisms, such as Chlamydia trachomatis, have also been associated with chronic prostatic infection, although this attribution remains speculative. C. trachomatis has been isolated from the prostate and in such cases appears to reside in prostate tissue as opposed to represent a contaminant from the urethra [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23496/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Some studies have shown that men with chronic prostatitis without a clear bacterial etiology had detectable chlamydial antigen in urine or prostatic secretions more frequently than men with pelvic pain but no signs of prostatic inflammation (21 to 25 versus 0 to 6 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23496/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rarely, fungi or Mycobacterium tuberculosis may be involved in chronic prostatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23496/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Patients with underlying immunosuppression may be more likely to have prostatic involvement with atypical organisms. As an example, in a series of patients with HIV-related immunosuppression and a history of treated cryptococcal meningitis, Cryptococcus neoformans could be isolated from prostatic secretions at a time when the organism was absent in blood or cerebrospinal fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23496/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14689254\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presentation of chronic bacterial prostatitis can be quite subtle. Classically, men present with symptoms of recurrent urinary tract infection (frequency, dysuria, urgency, perineal discomfort, and perhaps a low-grade fever) with repeated isolation of the same organism from the urine. However, this presentation is reported by the minority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23496/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some men may be asymptomatic and have only incidentally noted persistent or recurrent bacteriuria. Other symptoms can include pain (in the perineum, lower abdomen, testicles, penis, and with ejaculation), bladder irritation, bladder outlet obstruction, and sometimes blood in the semen. Sexual dysfunction may accompany chronic bacterial prostatitis, although it does not clearly occur more commonly than in men of a similar age without prostatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23496/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On rectal examination, there may be prostatic hypertrophy, tenderness, edema, and nodularity. However, the prostate exam is frequently normal.",
"   </p>",
"   <p>",
"    Laboratory findings that suggest inflammation or infection, such as elevated serum leukocytes or inflammatory markers, may be absent. In an analysis of participants in a trial of treatment for documented chronic bacterial prostatitis, an elevated prostatic specific antigen (&gt;4",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    was detected in only about 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23496/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14689261\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic standard for bacterial prostatitis is the finding of bacteria at higher levels in prostatic fluid compared with urethral and bladder specimens. However, maneuvers to express prostatic fluid can be cumbersome and are rarely performed in clinical practice. Instead, chronic bacterial prostatitis is often presumptively diagnosed and empirically treated with antimicrobials when men present with chronic (eg, longer than three months) or recurrent urogenital symptoms, particularly if bacteriuria is also present. Because of the insensitivity of these clinical findings and the therapeutic implication of a prolonged course of antibiotics, we favor obtaining prostatic specimens for analysis and culture to confirm the prostate as the site of infection in men with chronic symptoms of prostatitis, incidental bacteriuria, or recurrent urinary tract infections in the absence of other risk factors, such as bladder catheterization. In most cases, this is best performed in a urologist&rsquo;s office, where there is a greater level of experience in obtaining prostatic secretions and thus a greater likelihood of a microbial diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14689268\">",
"    <span class=\"h2\">",
"     Obtaining and testing prostatic specimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostatic specimens can be obtained by collecting expressed prostatic fluid and a urine sample expressed following prostatic massage. For primary care doctors and internal medicine subspecialists, obtaining fluid or tissue from the prostate is difficult and semen cultures are not standard. Thus, referral to a urologist can be helpful for men with long-standing or refractory prostatic symptoms to obtain such specimens for diagnosis.",
"   </p>",
"   <p>",
"    The classic method for localizing pathogens in the lower urinary tract and thus evaluating for bacterial prostatitis is the Meares-Stamey four-glass test [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23496/abstract/9\">",
"     9",
"    </a>",
"    ]. It involves first cleaning the periurethral area and then collecting the first 5 to 10 mL void of urine (VB1, urethral sample) and a midstream sample (VB2, bladder sample). The patient should stop voiding before the bladder is empty and the prostate is then digitally massaged by applying gentle pressure moving from the superior portion to the apex for about one minute. Any prostatic secretions that are expressed (EPS, prostatic sample) and the first 5 to 10 mL of subsequently voided urine (VB3, prostatic sample) are collected (",
"    <a class=\"graphic graphic_figure graphicRef69118 \" href=\"UTD.htm?15/48/16143\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/41/24214?source=see_link\">",
"     \"Urine sampling and culture in the diagnosis of urinary tract infection in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The finding of pathogens on culture of prostatic samples (EPS and VB3) exclusively or at a level 10 times higher than in urethral and bladder samples (VB1 and VB2) is diagnostic of bacterial prostatitis. For the test to be interpretable, the colony count in VB2 must be less than",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      3",
"     </sup>",
"     /mL,",
"    </span>",
"    since bladder bacteriuria prevents identification of the frequently small number of organisms from the prostate. Chronic prostatitis is suspected when VB3 has more than 12 leukocytes per high power field; more than 20 leukocytes per high power field is generally diagnostic unless leukocytes were also present in VB2 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23496/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the four-glass test is described extensively in the literature, it appears to be infrequently used in practice. In one survey of urologists in which 64 percent responded, 33 and 47 percent, respectively, said that they never or rarely performed the four-glass test [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23496/abstract/27\">",
"     27",
"    </a>",
"    ]. Furthermore, the results of the test apparently did not influence the use of antibiotics, since urologists who used the test routinely did not differ in antibiotic prescribing from others who used it less often.",
"   </p>",
"   <p>",
"    A simpler, &ldquo;two-glass&rdquo; method, in which cultures from only the post-prostatic massage urine (VB3) are compared with the pre-massage bladder urine sample (VB2), has been suggested as an alternate method, with a 100 percent positive and 96 percent negative predictive value when compared with the four-glass test [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23496/abstract/28\">",
"     28",
"    </a>",
"    ]. Although this test has slightly lower sensitivity than the four-glass test, it is a preferred alternative compared with not performing any cultures of prostatic samples.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14689275\">",
"    <span class=\"h2\">",
"     Evaluating the microbial etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cultures of post-prostatic massage urine or expressed prostatic secretions are almost always positive in chronic bacterial prostatitis (",
"    <a class=\"graphic graphic_table graphicRef75162 \" href=\"UTD.htm?23/22/23916\">",
"     table 1",
"    </a>",
"    ) and thus reveal the bacterial etiology. The repeated isolation of the same organism from urine cultures over time also suggests the etiologic agent. However, sexually transmitted organisms that may play a role in chronic bacterial prostatitis, such as C. trachomatis, will not grow in routine culture. Thus, in men who are sexually active and have clinical evidence of chronic prostatitis, but negative results of urine and prostatic secretion cultures, nucleic acid amplification testing for C. trachomatis on urine or urethral swabs can be diagnostically useful [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23496/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14689240\">",
"     'Microbiology'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10729?source=see_link&amp;anchor=H22688671#H22688671\">",
"     \"Clinical manifestations and diagnosis of Chlamydia trachomatis infections\", section on 'Diagnosis of chlamydial infections'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14689289\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main differential diagnosis to consider in a patient with symptoms and signs consistent with chronic bacterial prostatitis is chronic",
"    <span class=\"nowrap\">",
"     prostatitis/chronic",
"    </span>",
"    pelvic pain syndrome",
"    <span class=\"nowrap\">",
"     (CP/CPPS),",
"    </span>",
"    in whom the symptoms may be the same, but there is no clear evidence of a bacterial infection. (See",
"    <a class=\"local\" href=\"#H14689079\">",
"     'Definitions'",
"    </a>",
"    above.) This distinction is not always readily established; however, as cultures of prostatic specimens are infrequently performed in clinical practice and atypical, fastidious pathogens have been implicated as occasional causes of chronic bacterial prostatitis. (See",
"    <a class=\"local\" href=\"#H14689240\">",
"     'Microbiology'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H14689275\">",
"     'Evaluating the microbial etiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Furthermore, some patients with",
"    <span class=\"nowrap\">",
"     CP/CPPS",
"    </span>",
"    respond to antibiotic therapy despite lack of a clear bacterial infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23496/abstract/29\">",
"     29",
"    </a>",
"    ]. Thus, an initial antimicrobial course is often given to patients with symptoms of prostatitis to treat a potential bacterial infection, and the diagnosis of",
"    <span class=\"nowrap\">",
"     CP/CPPS",
"    </span>",
"    is entertained among those patients who do not respond or relapse and continue to have no clear evidence of infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17720?source=see_link&amp;anchor=H334781393#H334781393\">",
"     \"Chronic prostatitis/chronic pelvic pain syndrome\", section on 'Differential diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17720?source=see_link&amp;anchor=H8#H8\">",
"     \"Chronic prostatitis/chronic pelvic pain syndrome\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Noninflammatory disorders of the prostate, bladder, and urinary tract can also lead to persistent irritative (urgency, frequency, nocturia) and obstructive (slow stream, hesitancy, dribbling) urinary symptoms that can be seen with chronic bacterial prostatitis. The evaluation of men with lower urinary tract symptoms is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11290?source=see_link\">",
"     \"Lower urinary tract symptoms in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14689296\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolonged antibiotic therapy (eg, at least six weeks) with an agent that has good penetration into the prostatic tissue is generally necessary for treatment of chronic bacterial prostatitis. Nevertheless, the infection frequently recurs. A fluoroquinolone is generally the drug of choice for both initial and recurrent episodes, if organism susceptibility and patient tolerance allow.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     Trimethoprim-sulfamethoxazole",
"    </a>",
"    is an adequate alternative regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19592317\">",
"    <span class=\"h2\">",
"     Antimicrobial penetration into prostatic tissue",
"    </span>",
"    &nbsp;&mdash;&nbsp;The barrier between the microcirculation and the prostate gland stroma limits drug entry to passive diffusion, which only permits non-protein-bound, lipophilic antimicrobial agents to reach therapeutic levels within the gland. In addition, the low pH of prostatic fluid permits antibiotics with alkaline pK",
"    <sub>",
"     a",
"    </sub>",
"    s (such as quinolones and sulfonamides) to achieve high concentrations in prostatic tissue more readily than antibiotics with acidic pK",
"    <sub>",
"     a",
"    </sub>",
"    s. Other agents with good to excellent penetration into prostatic fluid and tissue include tetracyclines and macrolides [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23496/abstract/30\">",
"     30",
"    </a>",
"    ]. However, antibiotic prostatic penetration in the setting of inflammation occurs more readily [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23496/abstract/31\">",
"     31",
"    </a>",
"    ]. Nevertheless, ideal choices for therapy of bacterial prostatitis include those agents that have optimal prostatic penetration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14689303\">",
"    <span class=\"h2\">",
"     Initial antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men with an initial episode of chronic bacterial prostatitis caused by a susceptible organism, we suggest antibiotic treatment with a fluoroquinolone. In cases of patient intolerance or bacterial drug resistance, antimicrobial choice should be guided by susceptibility testing. Fluoroquinolones are generally given for at least six weeks. Courses exceeding this duration may be warranted for patients who have a relatively difficult to treat organism or who cannot tolerate first-line therapy and need other agents. Patients should be counselled about and monitored for potential adverse effects associated with such prolonged use of antibiotics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28618?source=see_link&amp;anchor=H24#H24\">",
"     \"Fluoroquinolones\", section on 'Adverse reactions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38438?source=see_link&amp;anchor=H8#H8\">",
"     \"Trimethoprim-sulfamethoxazole: An overview\", section on 'Adverse effects and precautions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The selection of agents and duration of therapy for chronic bacterial prostatitis have not been extensively studied using comparative trials with antimicrobial agents from varying classes. Moreover, studies of antimicrobial treatment of chronic prostatitis often include men with inflammatory chronic",
"    <span class=\"nowrap\">",
"     prostatitis/chronic",
"    </span>",
"    pelvic pain syndrome, in which an infectious etiology is not clearly established. (See",
"    <a class=\"local\" href=\"#H14689079\">",
"     'Definitions'",
"    </a>",
"    above.) Nevertheless, in studies restricted to men with documented chronic bacterial prostatitis, various fluoroquinolone regimens (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    500 mg PO every 12 hours or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    500 mg PO daily) have six-month clinical cure rates of about 60 to 70 percent when given for four weeks or longer [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23496/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. Shorter courses of higher doses of fluoroquinolones have been associated with an increased likelihood of relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23496/abstract/36\">",
"     36",
"    </a>",
"    ]. A longer course of six or more weeks may be needed to achieve clinical cure with other agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23496/abstract/9,11\">",
"     9,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rising rate of resistance of Enterobacteriaceae to fluoroquinolones and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13561?source=see_link&amp;anchor=H899949163#H899949163\">",
"     \"Acute uncomplicated cystitis and pyelonephritis in women\", section on 'Antimicrobial resistance'",
"    </a>",
"    ) and the frequency of allergies or intolerance to these agents complicate treatment decisions for chronic bacterial prostatitis. There are limited data on management of such cases. Based on biological plausibility, some experts use a prolonged course of other antimicrobials (including tetracyclines, macrolides, and cephalosporins) chosen based on susceptibility results and monitor closely for clinical response and relapse. In some cases, the resistance pattern may only leave intravenous agents as effective options. In cases of complicated drug resistance or intolerance, consultation with an expert in the treatment of prostatitis is advised.",
"   </p>",
"   <p>",
"    Of note, although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    is commonly used for lower urinary tract infections in women, we avoid this agent in men with prostatitis because of concern about poor tissue penetration and risk of adverse effects from prolonged use.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     Doxycycline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    are effective agents against C. trachomatis and are the agents of choice in prostatic infections associated with this organism [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23496/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. In a trial of 89 men with chronic prostatitis and laboratory evidence of C. trachomatis infection, men randomly assigned to azithromycin (500 mg daily for three days each week for three weeks) had higher rates of bacterial eradication (80 versus 39 percent) and clinical cure (69 versus 34 percent) compared with those who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (500 mg twice daily for 20 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23496/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14689310\">",
"    <span class=\"h2\">",
"     Management of recurrences",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic bacterial prostatitis often recurs and is usually treated with an additional course of antibiotics. Fluoroquinolones generally remain the treatment of choice for recurrent bacterial prostatitis, even if this class of drug was used for the initial treatment course, unless a resistant organism is suspected or detected. If the first course was four weeks or less, a longer second course of at least six weeks is recommended.",
"   </p>",
"   <p>",
"    The efficacy of fluoroquinolones in recurrent chronic bacterial prostatitis has been suggested by several small studies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23496/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. In one study of 33 men who had failed therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    , TMP-SMX, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"     norfloxacin",
"    </a>",
"    , and were then retreated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (500 mg twice daily) for two to four weeks, the following results were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23496/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of 26 patients with E. coli as the pathogen, 17 were cured at greater than one year follow-up. In another two patients, a second treatment course with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      was successful. Two patients withdrew from therapy due to adverse drug reactions.",
"     </li>",
"     <li>",
"      Therapy was successful in two of five with pathogens other than E. coli.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Furthermore, failures of initial fluoroquinolone therapy are not necessarily due to bacterial resistance and instead can also be related to underlying prostate disease, incomplete adherence, drug interactions that reduce fluoroquinolone bioavailability, or to some other less understood component. Thus, in patients who have relapsed or failed to respond following a course of a fluoroquinolone, causes of impaired bioavailability of the fluoroquinolone should be sought and, if possible, remedied. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28618?source=see_link&amp;anchor=H34#H34\">",
"     \"Fluoroquinolones\", section on 'Drug interactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, prolonged use of fluoroquinolones has been associated with several serious side effects, including Clostridium difficile associated diarrhea, central nervous system toxicity, and tendinopathy. As examples, tendinitis and tendon rupture have been reported in patients receiving prolonged fluoroquinolone therapy, especially in patients &gt;60 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23496/abstract/43\">",
"     43",
"    </a>",
"    ]. Among patients in this age group, those receiving glucocorticoids are at the highest risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28618?source=see_link&amp;anchor=H24#H24\">",
"     \"Fluoroquinolones\", section on 'Adverse reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In cases of bacterial resistance, patient intolerance, or concerns about prolonged use of fluoroquinolones,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    is an alternative. As above, a longer duration of therapy (at minimum, six weeks) may be needed to achieve clinical cure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/11/29873?source=see_link\">",
"       \"Patient information: Prostatitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14689331\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prostatitis can be divided into the following categories (",
"      <a class=\"graphic graphic_table graphicRef75162 \" href=\"UTD.htm?23/22/23916\">",
"       table 1",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H14689079\">",
"       'Definitions'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      I. Acute prostatitis",
"     </li>",
"     <li>",
"      II. Chronic bacterial prostatitis",
"     </li>",
"     <li>",
"      IIIA. Chronic",
"      <span class=\"nowrap\">",
"       prostatitis/pelvic",
"      </span>",
"      pain syndrome, inflammatory",
"     </li>",
"     <li>",
"      IIIB. Chronic",
"      <span class=\"nowrap\">",
"       prostatitis/pelvic",
"      </span>",
"      pain syndrome, noninflammatory",
"     </li>",
"     <li>",
"      IV. Asymptomatic inflammatory prostatitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall, prostatitis is a very common presentation in the clinical setting and tends to occur in young and middle-aged men. However, actual bacterial infections make up a minority of these cases. Gram-negative rods and Escherichia coli in particular, are the most common etiologic agents of chronic bacterial prostatitis. Other organisms, including enterococci, staphylococci, streptococci, and Chlamydia trachomatis have also been associated with chronic prostatic infection. (See",
"      <a class=\"local\" href=\"#H14689086\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14689240\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Drug entry into the prostate is limited. Fluoroquinolones and sulfonamides achieve the highest concentrations in prostatic tissue; tetracyclines and macrolides can also reach therapeutic levels in the prostate. (See",
"      <a class=\"local\" href=\"#H19592317\">",
"       'Antimicrobial penetration into prostatic tissue'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical presentation of chronic bacterial prostatitis is typically subtle. Classically, men present with symptoms of recurrent urinary tract infection with repeated isolation of the same organism from the urine. However, some men may be asymptomatic with only persistent or recurrent bacteriuria. Other lower urinary tract symptoms include pain and irritative and obstructive symptoms. (See",
"      <a class=\"local\" href=\"#H14689254\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In clinical practice, chronic bacterial prostatitis is usually presumptively diagnosed in men with chronic or recurrent urogenital symptoms",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      persistent bacteriuria. Ideally, bacterial infection of the prostate should be confirmed with comparative analysis of cultures from prostatic secretions and urine obtained prior to and following prostatic massage (",
"      <a class=\"graphic graphic_figure graphicRef69118 \" href=\"UTD.htm?15/48/16143\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14689261\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14689268\">",
"       'Obtaining and testing prostatic specimens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The bacterial etiology can usually be identified through culture of urine or expressed prostatic secretions. In sexually active men with suspected chronic bacterial prostatitis, but no bacterial organism on routine culture, nucleic acid amplification testing for C. trachomatis on urine or urethral swabs should be performed. (See",
"      <a class=\"local\" href=\"#H14689275\">",
"       'Evaluating the microbial etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main differential diagnosis to consider in a patient with symptoms and signs consistent with chronic bacterial prostatitis is chronic",
"      <span class=\"nowrap\">",
"       prostatitis/chronic",
"      </span>",
"      pelvic pain syndrome",
"      <span class=\"nowrap\">",
"       (CP/CPPS).",
"      </span>",
"      An initial antimicrobial course is often given presumptively to patients with symptoms of prostatitis without a documented bacterial infection, and the diagnosis of",
"      <span class=\"nowrap\">",
"       CP/CPPS",
"      </span>",
"      is then entertained among those patients who do not respond or relapse and continue to have no clear evidence of infection. (See",
"      <a class=\"local\" href=\"#H14689289\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17720?source=see_link\">",
"       \"Chronic prostatitis/chronic pelvic pain syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with an initial episode of chronic bacterial prostatitis, we suggest treatment with a fluoroquinolone as long as organism susceptibility and patient tolerance allow (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       Trimethoprim-sulfamethoxazole",
"      </a>",
"      is an alternative option. Fluoroquinolones are typically given for at least six weeks for probable or documented chronic bacterial prostatitis. Longer courses may be indicated for patients who are infected with a relatively difficult to treat organism or are given a nonfluoroquinolone antibiotic for therapy. Shorter courses (eg, two to four weeks) are sometimes used when the diagnosis is uncertain and the possibility of",
"      <span class=\"nowrap\">",
"       CP/CPPS",
"      </span>",
"      is being entertained. Documented C. trachomatis infections can be treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H14689303\">",
"       'Initial antibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recurrences of chronic bacterial prostatitis are common and warrant a second course of antibiotics. Possible causes of treatment failure, including antibiotic resistance, incomplete adherence, and impaired drug absorption, should be evaluated. For men with a recurrent episode of chronic bacterial prostatitis, we suggest treatment with a fluoroquinolone regardless of the initial antibiotic choice unless there is suspicion of a resistant organism or poor drug bioavailability (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       Trimethoprim-sulfamethoxazole",
"      </a>",
"      is an alternate agent. If the initial course of therapy was less than six weeks, a longer subsequent course is indicated. (See",
"      <a class=\"local\" href=\"#H14689310\">",
"       'Management of recurrences'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/1\">",
"      Pontari MA, Joyce GF, Wise M, et al. Prostatitis. J Urol 2007; 177:2050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/2\">",
"      Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA 1999; 282:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/3\">",
"      Krieger JN, Jacobs RR, Ross SO. Does the chronic prostatitis/pelvic pain syndrome differ from nonbacterial prostatitis and prostatodynia? J Urol 2000; 164:1554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/4\">",
"      Collins MM, Stafford RS, O'Leary MP, Barry MJ. How common is prostatitis? A national survey of physician visits. J Urol 1998; 159:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/5\">",
"      de la Rosette JJ, Hubregtse MR, Meuleman EJ, et al. Diagnosis and treatment of 409 patients with prostatitis syndromes. Urology 1993; 41:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/6\">",
"      Bradshaw CS, Tabrizi SN, Read TR, et al. Etiologies of nongonococcal urethritis: bacteria, viruses, and the association with orogenital exposure. J Infect Dis 2006; 193:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/7\">",
"      Yoon BI, Kim S, Han DS, et al. Acute bacterial prostatitis: how to prevent and manage chronic infection? J Infect Chemother 2012; 18:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/8\">",
"      Zhao WP, Li YT, Chen J, et al. Prostatic calculi influence the antimicrobial efficacy in men with chronic bacterial prostatitis. Asian J Androl 2012; 14:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/9\">",
"      Schaeffer AJ. Clinical practice. Chronic prostatitis and the chronic pelvic pain syndrome. N Engl J Med 2006; 355:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/10\">",
"      Naber KG, Busch W, Focht J. Ciprofloxacin in the treatment of chronic bacterial prostatitis: a prospective, non-comparative multicentre clinical trial with long-term follow-up. The German Prostatitis Study Group. Int J Antimicrob Agents 2000; 14:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/11\">",
"      Lipsky BA, Byren I, Hoey CT. Treatment of bacterial prostatitis. Clin Infect Dis 2010; 50:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/12\">",
"      Cornia PB, Takahashi TA, Lipsky BA. The microbiology of bacteriuria in men: a 5-year study at a Veterans' Affairs hospital. Diagn Microbiol Infect Dis 2006; 56:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/13\">",
"      Krieger JN, Ross SO, Limaye AP, Riley DE. Inconsistent localization of gram-positive bacteria to prostate-specific specimens from patients with chronic prostatitis. Urology 2005; 66:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/14\">",
"      Krieger JN, McGonagle LA. Diagnostic considerations and interpretation of microbiological findings for evaluation of chronic prostatitis. J Clin Microbiol 1989; 27:2240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/15\">",
"      Bruce AW, Reid G. Prostatitis associated with Chlamydia trachomatis in 6 patients. J Urol 1989; 142:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/16\">",
"      Poletti F, Medici MC, Alinovi A, et al. Isolation of Chlamydia trachomatis from the prostatic cells in patients affected by nonacute abacterial prostatitis. J Urol 1985; 134:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/17\">",
"      Mutlu N, Mutlu B, Culha M, et al. The role of Chlamydia trachomatis in patients with non-bacterial prostatitis. Int J Clin Pract 1998; 52:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/18\">",
"      Ostaszewska I, Zdrodowska-Stefanow B, Badyda J, et al. Chlamydia trachomatis: probable cause of prostatitis. Int J STD AIDS 1998; 9:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/19\">",
"      G&uuml;m&uuml; B, Sengil AZ, Solak M, et al. Evaluation of non-invasive clinical samples in chronic chlamydial prostatitis by using in situ hybridization. Scand J Urol Nephrol 1997; 31:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/20\">",
"      Meares EM Jr. Prostatitis: A review. Urol Clin North Am 1975; 2:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/21\">",
"      Chuang AY, Tsou MH, Chang SJ, et al. Mycobacterium abscessus granulomatous prostatitis. Am J Surg Pathol 2012; 36:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/22\">",
"      Larsen RA, Bozzette S, McCutchan JA, et al. Persistent Cryptococcus neoformans infection of the prostate after successful treatment of meningitis. California Collaborative Treatment Group. Ann Intern Med 1989; 111:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/23\">",
"      Orland SM, Hanno PM, Wein AJ. Prostatitis, prostatosis, and prostatodynia. Urology 1985; 25:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/24\">",
"      M&uuml;ller A, Mulhall JP. Sexual dysfunction in the patient with prostatitis. Curr Opin Urol 2005; 15:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/25\">",
"      Krieger JN, Egan KJ, Ross SO, et al. Chronic pelvic pains represent the most prominent urogenital symptoms of \"chronic prostatitis\". Urology 1996; 48:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/26\">",
"      Schaeffer AJ, Wu SC, Tennenberg AM, Kahn JB. Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen. J Urol 2005; 174:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/27\">",
"      McNaughton Collins M, Fowler FJ Jr, Elliott DB, et al. Diagnosing and treating chronic prostatitis: do urologists use the four-glass test? Urology 2000; 55:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/28\">",
"      Nickel JC, Shoskes D, Wang Y, et al. How does the pre-massage and post-massage 2-glass test compare to the Meares-Stamey 4-glass test in men with chronic prostatitis/chronic pelvic pain syndrome? J Urol 2006; 176:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/29\">",
"      Nickel JC, Downey J, Johnston B, et al. Predictors of patient response to antibiotic therapy for the chronic prostatitis/chronic pelvic pain syndrome: a prospective multicenter clinical trial. J Urol 2001; 165:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/30\">",
"      Charalabopoulos K, Karachalios G, Baltogiannis D, et al. Penetration of antimicrobial agents into the prostate. Chemotherapy 2003; 49:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/31\">",
"      Aagaard J, Madsen PO. Bacterial prostatitis: new methods of treatment. Urology 1991; 37:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/32\">",
"      Giannarini G, Mogorovich A, Valent F, et al. Prulifloxacin versus levofloxacin in the treatment of chronic bacterial prostatitis: a prospective, randomized, double-blind trial. J Chemother 2007; 19:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/33\">",
"      Naber KG, Roscher K, Botto H, Schaefer V. Oral levofloxacin 500 mg once daily in the treatment of chronic bacterial prostatitis. Int J Antimicrob Agents 2008; 32:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/34\">",
"      Bundrick W, Heron SP, Ray P, et al. Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study. Urology 2003; 62:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/35\">",
"      Naber KG, European Lomefloxacin Prostatitis Study Group. Lomefloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis. Int J Antimicrob Agents 2002; 20:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/36\">",
"      Paglia M, Peterson J, Fisher AC, et al. Safety and efficacy of levofloxacin 750 mg for 2 weeks or 3 weeks compared with levofloxacin 500 mg for 4 weeks in treating chronic bacterial prostatitis. Curr Med Res Opin 2010; 26:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/37\">",
"      Martin DH, Mroczkowski TF, Dalu ZA, et al. A controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis. The Azithromycin for Chlamydial Infections Study Group. N Engl J Med 1992; 327:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/38\">",
"      Chiarini F, Mansi A, Tomao P, et al. Chlamydia trachomatis genitourinary infections: laboratory diagnosis and therapeutic aspects. Evaluation of in vitro and in vivo effectiveness of azithromycin. J Chemother 1994; 6:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/39\">",
"      Skerk V, Sch&ouml;nwald S, Krhen I, et al. Comparative analysis of azithromycin and ciprofloxacin in the treatment of chronic prostatitis caused by Chlamydia trachomatis. Int J Antimicrob Agents 2003; 21:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/40\">",
"      Weidner W, Schiefer HG. Chronic bacterial prostatitis: therapeutic experience with ciprofloxacin. Infection 1991; 19 Suppl 3:S165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/41\">",
"      Schaeffer AJ, Darras FS. The efficacy of norfloxacin in the treatment of chronic bacterial prostatitis refractory to trimethoprim-sulfamethoxazole and/or carbenicillin. J Urol 1990; 144:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/42\">",
"      Weidner W, Schiefer HG, Br&auml;hler E. Refractory chronic bacterial prostatitis: a re-evaluation of ciprofloxacin treatment after a median followup of 30 months. J Urol 1991; 146:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23496/abstract/43\">",
"      van der Linden PD, Sturkenboom MC, Herings RM, et al. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ 2002; 324:1306.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86802 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-77.94.48.4-BBE44F2A81-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_60_23496=[""].join("\n");
var outline_f22_60_23496=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14689331\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14689072\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14689079\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25602273\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14689086\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25602337\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14689240\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14689254\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14689261\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14689268\">",
"      Obtaining and testing prostatic specimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14689275\">",
"      Evaluating the microbial etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14689289\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14689296\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19592317\">",
"      Antimicrobial penetration into prostatic tissue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14689303\">",
"      Initial antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14689310\">",
"      Management of recurrences",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14689331\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/86802\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/86802|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/35/20023\" title=\"figure 1\">",
"      Prostate anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/48/16143\" title=\"figure 2\">",
"      Four glass test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/86802|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/22/23916\" title=\"table 1\">",
"      Classification prostatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/42/4776?source=related_link\">",
"      Acute bacterial prostatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13561?source=related_link\">",
"      Acute uncomplicated cystitis and pyelonephritis in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17720?source=related_link\">",
"      Chronic prostatitis/chronic pelvic pain syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10729?source=related_link\">",
"      Clinical manifestations and diagnosis of Chlamydia trachomatis infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28618?source=related_link\">",
"      Fluoroquinolones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11290?source=related_link\">",
"      Lower urinary tract symptoms in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/11/29873?source=related_link\">",
"      Patient information: Prostatitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38438?source=related_link\">",
"      Trimethoprim-sulfamethoxazole: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/41/24214?source=related_link\">",
"      Urine sampling and culture in the diagnosis of urinary tract infection in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_60_23497="Ataxia-telangiectasia";
var content_f22_60_23497=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ataxia-telangiectasia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/60/23497/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/60/23497/contributors\">",
"     Puneet Opal, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/60/23497/contributors\">",
"     Francisco A Bonilla, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/60/23497/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/60/23497/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/60/23497/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/60/23497/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/60/23497/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/60/23497/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary ataxia has a variety of causes. One cause is an autosomal recessive disorder associated with defective DNA repair mechanisms: ataxia-telangiectasia (AT; MIM 208900). Patients with AT develop progressive cerebellar ataxia, abnormal eye movements, other neurologic abnormalities, oculocutaneous telangiectasias, and immune deficiency.",
"   </p>",
"   <p>",
"    This topic will review the genetics and clinical aspects of AT. A closely related disorder, ataxia-telangiectasia-like disorder (ATLD), is also discussed in this review. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Ataxia-telangiectasia-like disorder'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The hereditary ataxias are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37433?source=see_link\">",
"     \"Overview of the hereditary ataxias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENETICS AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ataxia-telangiectasia (AT) is an autosomal recessive genetic disorder. The defective gene in AT has been mapped to chromosome 11q22.3, and designated the ATM gene (for AT Mutated) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The ATM gene product has one region similar to that of phosphatidylinositol (PI)-3 kinases and another region similar to DNA",
"    <span class=\"nowrap\">",
"     repair/cell",
"    </span>",
"    checkpoint genes. It is expressed in all tissues in the body.",
"   </p>",
"   <p>",
"    ATM is involved in the detection of DNA damage, and plays an important role in cell cycle progression [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/3\">",
"     3",
"    </a>",
"    ]. The latter function is exerted at the transition between the G1 and S phase, when a cell initiates DNA synthesis in preparation for DNA replication. It also functions at the G2 to M transition, during which the cell begins to divide.",
"   </p>",
"   <p>",
"    Thus, the ATM kinase appears to be involved in a surveillance mechanism that, in the presence of DNA damage, will stall progression of the cell cycle. This delay allows the cell to repair the damage, rather than passing on inappropriate genetic information to daughter cells.",
"   </p>",
"   <p>",
"    Our understanding of how the ATM kinase acts is increasing. In the presence of DNA damage, the ATM kinase phosphorylates the tumor suppressor protein p53 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/4\">",
"     4",
"    </a>",
"    ]. Phosphorylated p53 serves as a transcriptional activator of genes that cause cell cycle arrest or apoptosis. In the absence of ATM kinase, p53 does not become phosphorylated and cannot prevent the cell from moving into the next phase of the cell cycle.",
"   </p>",
"   <p>",
"    ATM also phosphorylates other proteins:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The tumor suppressor BRCA1, which is one of the genes implicated in breast cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]. This interaction may explain (at least in part) how inheriting a mutant ATM protein predisposes patients with AT as well as heterozygotes to breast cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/7-10\">",
"       7-10",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Heterozygotes'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The c-abl tyrosine kinase and the Nbs1 (Nijmegen breakage syndrome) protein, which also are involved in DNA repair, primarily in response to ionizing radiation [",
"      <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/11,12\">",
"       11,12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The eIF-4E-binding protein 1, which releases the translation initiation factor, eIF-4E, and stimulates protein synthesis in the presence of insulin [",
"      <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/13\">",
"       13",
"      </a>",
"      ]. This interaction may explain the poor growth and insulin resistance that are seen in patients with AT.",
"     </li>",
"     <li>",
"      Protein phosphatase 2A, which regulates the nuclear importation of histone deacetylase 4 (HDAC4) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. Hypophosphorylated HDAC4 translocates to the nucleus of neurons in ATM-deficient mice, resulting in histone deacetylation, altered neuronal gene expression, and neurodegeneration [",
"      <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the absence of the supervisory function of ATM, cells can build up somatic mutations, possibly leading to malignant transformation. The increased propensity for leukemias and lymphomas in AT may be related to the remarkable number of chromosomal translocations and inversions in lymphocytes that result from the DNA processing defect [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/16\">",
"     16",
"    </a>",
"    ]. These abnormalities predominantly involve the gene loci that generate mature immunoglobulin and T cell receptor genes via genetic rearrangement [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The defect in nuclear DNA repair in AT also explains the sensitivity of cells to ionizing radiation and radiomimetic chemicals [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/12,17,18\">",
"     12,17,18",
"    </a>",
"    ]. Mouse models of AT display many of the features of human disease, including growth retardation, immune system defects, and sensitivity to radiation, although they do not display some of the other features, such as the progressive ataxia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Heterozygotes appear to have missense mutations that, instead of producing no detectable ATM kinase (as is the case with null or truncating mutations), result in an abnormal protein that acts by dominantly interfering with the function of the normal allele (a dominant negative effect) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/21\">",
"     21",
"    </a>",
"    ]. This is proposed to account for the increased risk of solid tumors that is seen in these ATM heterozygotes. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Heterozygotes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Another possible role for ATM is the maintenance of mitochondrial homeostasis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/3\">",
"     3",
"    </a>",
"    ], in part via regulation of ribonucleotide reductase (RR), which is the rate limiting enzyme in the synthesis of deoxyribonucleoside triphosphates (dNTP) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/22\">",
"     22",
"    </a>",
"    ]. RR activity and dNTP synthesis are an important part of the mitochondrial DNA (mtDNA) replication and repair pathway. Experimental evidence suggests that ATM and RR normally regulate proper mtDNA copy number and expression, and that mutant ATM results in reduced RR activity or expression. This causes mtDNA depletion and disruption of mitochondrial homeostasis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/22\">",
"     22",
"    </a>",
"    ]. Impaired mitochondrial activity may contribute to the pathogenesis of AT, leading to clinical features such as ataxia, neurodegeneration, and premature aging [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/22-24\">",
"     22-24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both the central and peripheral nervous systems are involved in AT. The central nervous system abnormalities are more severe and are primarily characterized by cerebellar atrophy with particular loss of Purkinje cells [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/25\">",
"     25",
"    </a>",
"    ]. Histologic examination of the peripheral nerves reveals malformed nuclei in Schwann cells. The thymus usually is hypoplastic, with fewer lymphocytes and absence of Hassall corpuscles [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/26\">",
"     26",
"    </a>",
"    ]; these findings are consistent with the associated immune deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estimated incidence of AT is 1 in 20,000 to 100,000 live births. However, as many as 1.4 to 2.0 percent of Caucasians in the United States carry one defective AT gene [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/7,27\">",
"     7,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with AT who are homozygotes invariably suffer from progressive cerebellar ataxia, abnormal eye movements, other neurologic abnormalities, oculocutaneous telangiectasias, and immune deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Associated features include pulmonary disease, an increased incidence of malignancy, radiation sensitivity, and diabetes mellitus caused by insulin resistance. Each of these abnormalities presumably results from impaired protein function induced by the mutation in the AT gene. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Genetics and pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Neurologic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ataxia is the earliest clinical manifestation of AT [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Most children appear healthy for the first year of life and begin walking at a normal age, but are slow to develop fluidity of gait. They also have difficulty standing still without wobbling. Unlike most ataxic disorders, individuals with AT walk on an unusually narrow base, and young children often prefer to walk quickly or run. However, they fall less frequently than one might expect. Gross motor function remains abnormal but relatively stable until school age, and cerebral palsy is often misdiagnosed [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thereafter, gross and fine motor skills deteriorate, leading to reconsideration of the diagnosis of cerebral palsy rather than AT. At about the same time, children develop dysarthria and complex disorders of movement. By the second decade of life, most patients must rely on wheelchairs for mobility outside the home.",
"   </p>",
"   <p>",
"    Eye movements are often normal in preschoolers, but children later develop abnormalities of both voluntary and involuntary saccades and have difficulty moving their eyes and heads in smooth, coordinated pursuit of a moving target [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. In addition, there is delay in initiating eye movement, and the eyes move in a series of small jumps rather than in a single smooth motion.",
"   </p>",
"   <p>",
"    The most obvious early manifestation is oculomotor apraxia: the inability to coordinate head and eye movements naturally when shifting gaze rapidly (saccadic eye movements). The early eye movement control problems are primarily related to impaired saccadic initiation, saccadic hypometria, abnormal smooth pursuit, and difficulty suppressing the vestibulo-ocular reflex while tracking an object moving with head rotation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Visual performance progressively deteriorates, with signs that include periodic alternating nystagmus and impaired lateral end-gaze fixation, vertical gaze holding, and velocity storage. By the end of their first decade of life, most children with AT stop reading longer passages for content because of these difficulties, even though they are easily able to identify single words and short phrases. Acquired strabismus is also common.",
"   </p>",
"   <p>",
"    The majority of children with AT never attain normal speech due to problems with articulation, and speech further deteriorates after the age of five to eight years. There is a characteristic delay in the initiation of speech, and the speech is typically slow with inappropriate emphasis placed on single words or syllables. Progressive difficulty with chewing and swallowing develops over time, and aspiration is common in individuals over the age of 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the obvious cerebellar pathology, many of the motor difficulties of AT are extrapyramidal in nature. These include dystonia, chorea, delayed reaction time, facial hypomimia, and distal adventitious movements at rest [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/28\">",
"     28",
"    </a>",
"    ]. Peripheral axonal neuropathy is common [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. However, neuropathy contributes relatively little to functional impairment in AT given the severity of other movement deficits.",
"   </p>",
"   <p>",
"    In some cases, patients with AT develop a distally predominant pattern of lower motor neuron weakness due to anterior horn cell degeneration [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/38\">",
"     38",
"    </a>",
"    ], though this may be difficult to distinguish from a mixed motor-sensory axonal neuropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Telangiectasias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Telangiectasias of blood vessels are seen primarily on the bulbar conjunctivae and on exposed areas of the skin, typically the pinnae, nose, face, and neck. In most cases, they first appear when the child reaches three to five years of age. It is perhaps unfortunate that this disease is named ataxia-telangiectasia because the delayed appearance of telangiectasia often results in delayed diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Immune deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune deficiency, affecting both cellular and humoral immunity, occurs in approximately 70 percent of patients. The defect is quite variable but often manifests as recurrent sinopulmonary infections [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Infections outside of the respiratory tract are generally not increased in frequency, and opportunistic infections rarely occur [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/39\">",
"     39",
"    </a>",
"    ]. Infections may be the result of underlying immunodeficiency",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dysfunctional swallow with aspiration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11399544\">",
"    <span class=\"h2\">",
"     Pulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive pulmonary disease is a major cause of morbidity and mortality in patients with AT. Three major types of pulmonary involvement are associated with AT [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/41\">",
"     41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recurrent sinopulmonary infections and bronchiectasis",
"     </li>",
"     <li>",
"      Interstitial lung",
"      <span class=\"nowrap\">",
"       disease/pulmonary",
"      </span>",
"      fibrosis",
"     </li>",
"     <li>",
"      Neuromuscular abnormalities, including dysphagia, aspiration, and respiratory muscle weakness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Even in the absence of infection, patients with AT can develop interstitial lung disease, with symptoms including nonproductive cough, dyspnea, fever, tachypnea, hypoxemia, and crackles [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Many children with AT have difficulty with coordination of swallowing and may aspirate foods, liquids, and oral secretions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/35,43\">",
"     35,43",
"    </a>",
"    ]. Dysphagia often presents in the second decade of life. Furthermore, neuromuscular weakness can result in decreased tidal volumes and ineffective cough [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beyond age 10 years, the incidence of cancer in AT is 1 percent per year; overall, approximately 10 to 20 percent of patients will develop malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Of these neoplasms, 85 percent are lymphomas and acute leukemias, but a predisposition to other cancers (such as breast cancer) may also exist.",
"   </p>",
"   <p>",
"    AT cells are susceptible to damage by ionizing radiation, or chemotherapeutic agents that cause double-stranded breaks in DNA. Deaths caused by extreme sensitivity to chemotherapy for malignancy have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/47\">",
"     47",
"    </a>",
"    ], and the incidence of late complications following radiation therapy may be higher in some affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Laboratory abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most consistent laboratory abnormality is an elevation of serum alpha-fetoprotein (AFP) level in children over the age of eight months [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/50\">",
"     50",
"    </a>",
"    ]. The level does not necessarily rise over time, and does not correlate with severity of disease.",
"   </p>",
"   <p>",
"    There is a wide range of laboratory abnormalities involving both humoral and cell-mediated immunity among individuals with AT. However, it should be stressed that despite the high frequency of laboratory abnormalities, there is a striking lack of opportunistic infections and the risk for infection has never been closely correlated with any single or group of laboratory abnormalities. The abnormalities include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunoglobulin deficiency, especially absence or marked reduction of IgA, IgG2, and other IgG subclasses [",
"      <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/51,52\">",
"       51,52",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/60/13258?source=see_link\">",
"       \"IgG subclass deficiency\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Inability to produce antibodies to polysaccharide antigens such as those forming the capsule of pathogenic bacteria such as the pneumococcus [",
"      <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/53,54\">",
"       53,54",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Oligoclonal gammopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/55\">",
"       55",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Lymphopenia with the most prominent reduction in T cells [",
"      <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/56,57\">",
"       56,57",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Occasional patients have severe panhypogammaglobulinemia or present with a picture compatible with severe combined immunodeficiency disease. In the vast majority of AT patients, immunodeficiency is not progressive, but humoral immune deficiency becomes more severe with increasing age in 5 to 10 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Spontaneous cytogenetic abnormalities, including chromatid gaps, chromosomal breakage, translocations, and rearrangements are common, especially involving the immunoglobulin and T cell receptor gene loci on chromosomes 7 and 14 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Variant AT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is mounting evidence describing a phenotype of \"variant ataxia-telangiectasia\" (variant AT) that has a milder course than classic AT, perhaps on the basis of mutations that result in expression of residual ATM protein and kinase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/60-63\">",
"     60-63",
"    </a>",
"    ]. The most common presenting features are movement disorders such as tremor, dystonia, and choreoathetosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the largest series of 13 patients with variant AT, typical clinical manifestations were childhood onset of extrapyramidal symptoms and signs, mainly choreoathetosis or rest tremor, followed a few years later by cerebellar ataxia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/64\">",
"     64",
"    </a>",
"    ]. Axonal neuropathy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lower motor neuron weakness were additional features. All patients had elevated serum alpha fetoprotein. However, approximately one-half did not develop oculomotor apraxia, and a similar proportion did not have ocular telangiectasia, whereas both are hallmarks of classic AT. Another report found ATM mutations in 12 of 35 subjects with dystonia and Canadian Mennonite heritage [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/65\">",
"     65",
"    </a>",
"    ]. Some of the subjects had myoclonus, whereas none had prominent ocular telangiectasia, oculomotor apraxia, or ataxia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Heterozygotes",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, up to 2 percent of Caucasians in the United States carry one defective AT gene [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/7,27\">",
"     7,27",
"    </a>",
"    ]. Heterozygotes have none of the classical clinical manifestations of AT. However, they may have a higher incidence of malignancy at a younger age, and perhaps coronary heart disease. In one retrospective cohort study of 405 grandparents of patients with AT, carriers died on average seven to eight years earlier than did noncarriers [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/66\">",
"     66",
"    </a>",
"    ]. Most of the excess deaths were caused by cancer, and a trend toward increased mortality caused by coronary heart disease was found. Compared with noncarriers, carriers who died of coronary disease were 11 years younger.",
"   </p>",
"   <p>",
"    The spectrum of malignancies observed in blood relatives is quite different from that of people with AT, being much more heavily weighted toward solid tumors. Among the cancers associated with AT heterozygosity, the most significant relative risks are observed for female breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/7-9,46,66-68\">",
"     7-9,46,66-68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relationship between heterozygosity for AT and breast cancer risk has been controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/69\">",
"     69",
"    </a>",
"    ]. Early studies were limited by a lack of a reliable assay that could identify carriers. After the gene was identified in 1995, a significantly increased risk of breast cancer (two- to fivefold) was identified in many but not all studies of carriers among AT families [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/8-10,67,68,70\">",
"     8-10,67,68,70",
"    </a>",
"    ]. However, when screening for truncating mutations that characterize 60 to 70 percent of AT homozygotes was extended to large cohorts of people with breast cancer, an excess of truncating mutations could not be demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/71\">",
"     71",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Genetics and pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    One explanation for these disparate results (and for the different cancer phenotypes that characterize AT heterozygotes versus homozygotes) may be that heterozygotes have missense variants (in particular, ones that do not cause AT) that predispose to breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/21,72,73\">",
"     21,72,73",
"    </a>",
"    ]. These variants, instead of producing no detectable ATM kinase (as is the case with null or truncating mutations), result in an abnormal protein that acts by dominantly interfering with the function of the normal allele (a dominant negative effect). In fact, putative missense mutations have been reported in a number of studies of breast cancer populations where ATM truncating mutations have not been found [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/71,74\">",
"     71,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another explanation is that only a subset of ATM mutations, defined by biological characteristics, confers a risk of breast cancer, although the mutations are not as highly penetrant for breast cancer as are BRCA1 or BRCA2 mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/68,73,75\">",
"     68,73,75",
"    </a>",
"    ]. As an example, a clear association between truncating ATM mutations and breast cancer risk was shown in a report using index cases from families with at least three breast cancers in which BRCA1 and BRCA2 mutations were ruled out [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/68\">",
"     68",
"    </a>",
"    ]. Nine ATM mutations predicted to result in premature truncation or exon skipping were identified in 443 familial breast cancer cases (2 percent compared to 0.4 percent of 521 controls). In all, there were 12 ATM mutations (truncating, splicing, or missense) in cases compared to two in controls. Thus, the relative risk of breast cancer associated with ATM mutations was estimated to be 2.37 (an estimate which is consistent with studies of AT families), and equivalent to a breast cancer attributable fraction of 0.86 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=see_link&amp;anchor=H20#H20\">",
"     \"Characteristics of hereditary breast and ovarian cancer syndromes\", section on 'Ataxia-telangiectasia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, taken together, the available evidence suggests that there is an approximately twofold increase in the risk of breast cancer associated with heterozygosity for ATM mutations that cause AT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Criteria have been proposed to establish the diagnosis of ataxia-telangiectasia (AT) (",
"    <a class=\"graphic graphic_table graphicRef57053 \" href=\"UTD.htm?40/62/41963\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/76\">",
"     76",
"    </a>",
"    ]. The diagnosis is established by the presence of characteristic clinical findings (particularly progressive cerebellar ataxia) and identification of disabling mutations on both alleles for the AT mutated gene (ATM). It is supported by serum IgA at least two standard deviations below normal for age and by increased spontaneous and radiation-induced chromosome fragility in cultured cells.",
"   </p>",
"   <p>",
"    In the appropriate clinical setting, the finding of a serum alpha-fetoprotein (AFP) at least two standard deviations above normal for age is diagnostic of the disorder, with a sensitivity of approximately 95 percent. In patients older than six months of age, an AFP concentration &gt;30",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    is be considered abnormal [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/77\">",
"     77",
"    </a>",
"    ]. It should be remembered that telangiectasia usually appears after age five years and that not all patients with AT have elevated levels of AFP.",
"   </p>",
"   <p>",
"    Another diagnostic method involves a rapid immunoblotting assay for ATM protein [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/78\">",
"     78",
"    </a>",
"    ], which is severely depleted in most patients with AT [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/29,79\">",
"     29,79",
"    </a>",
"    ]. However, this procedure requires a large blood sample and is available in few laboratories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;AT can be difficult to distinguish clinically from other chronic ataxic syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/80\">",
"     80",
"    </a>",
"    ]. If ataxia develops early, it may be misdiagnosed as an ataxic variety of cerebral palsy, particularly because mental retardation is not a feature. When the onset is delayed, AT most often is mistaken for Friedreich ataxia, a disorder that now is diagnosed by genetic testing for mutation in the frataxin gene. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15432?source=see_link\">",
"     \"Friedreich ataxia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several diseases mirror the neurologic features of ataxia-telangiectasia, but result from defects in genes other than ATM. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ataxia-ocular apraxia type 1",
"     </li>",
"     <li>",
"      Ataxia-ocular apraxia type 2",
"     </li>",
"     <li>",
"      Ataxia-telangiectasia-like disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Ataxia-ocular apraxia type 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ataxia-ocular apraxia type 1 (AOA1) is an autosomal recessive disorder characterized by cerebellar ataxia, oculomotor apraxia, and cerebellar atrophy, and a severe axonal sensorimotor neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/81-85\">",
"     81-85",
"    </a>",
"    ]. Additional manifestations include hypoalbuminemia and elevation of serum total cholesterol. AOA1 lacks telangiectasia and the other non-neurologic features of ataxia-telangiectasia.",
"   </p>",
"   <p>",
"    AOA1 is caused by mutations in the APTX gene that encodes aprataxin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. Most reported cases are of Portuguese, Italian, and Japanese descent.",
"   </p>",
"   <p>",
"    A form of ataxia associated with muscle coenzyme Q10 deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/86,87\">",
"     86,87",
"    </a>",
"    ] has been linked to the same APTX gene and is probably the same disease as AOA1 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/88,89\">",
"     88,89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Ataxia-ocular apraxia type 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ataxia-ocular apraxia type 2 (AOA2) is associated with a progressive cerebellar ataxia, a variable presence of oculomotor apraxia, distal amyotrophy, sensory and motor axonal neuropathy, and elevations in serum alpha-fetoprotein [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/90-94\">",
"     90-94",
"    </a>",
"    ]. Patients have no evidence of chromosomal instability or sensitivity to ionizing radiation. AOA2 is caused by mutations in the SETX gene on chromosome 9q34 coding for senataxin, a DNA and RNA helicase [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/91,93\">",
"     91,93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Ataxia-telangiectasia-like disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ataxia-telangiectasia-like disorder (ATLD; MIM 604391) has been identified in only a small number of individuals. However, it is estimated that as many as 5 percent of AT cases may be incorrectly diagnosed and actually have ATLD, given the similarity in clinical manifestations and coding sizes of the two affected genes.",
"   </p>",
"   <p>",
"    ATLD is caused by mutations of the MRE11A gene, which encodes a protein involved with ATM in double strand DNA break recognition and repair [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Affected patients have progressive ataxia without telangiectasia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. The overall neurologic phenotype is similar to that of AT, although the rate of neurodegeneration appears to be slower and most ATLD patients are still ambulatory in their late teens.",
"   </p>",
"   <p>",
"    The laboratory findings in ATLD are similar, but not identical to those seen in AT. Peripheral blood lymphocytes have chromosomal breaks in the basal state and an increase in chromatid-type damage after exposure to ionizing radiation. However, serum levels of alpha-fetoprotein and immunoglobulins are normal.",
"   </p>",
"   <p>",
"    The diagnosis of ATLD can be established with certainty only by finding mutations in both alleles of the MRE11A gene.",
"   </p>",
"   <p>",
"    The prognosis of patients with ATLD is unclear, since there are only a few recognized subjects with the disorder. In general, affected patients appear to have a slower pace of neurodegeneration than patients with AT. The risk for development of chronic lung disease or malignancy is unknown.",
"   </p>",
"   <p>",
"    The management of patients with ATLD is the same as for those with AT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ataxia-telangiectasia is a difficult disease to treat and has a poor prognosis because of its multisystem involvement. No disease-modifying treatment exists for the ataxic syndrome or the progressive cerebellar neurodegeneration. Many patients with AT succumb to progressive pulmonary disease caused by repeated infection or to cancer, and the median age at death is approximately 25 years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/98\">",
"     98",
"    </a>",
"    ]. Presently no therapies significantly alter the course of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11401238\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current management strategies for patients with AT are based upon the treatment of disease manifestations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute infection should be treated with appropriate antibiotics and simple maneuvers such as postural drainage. Antibiotic prophylaxis should be considered in patients with recurrent sinopulmonary bacterial infections. Chest clearance techniques may be helpful in patients with acute or chronic infections [",
"      <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A trial of glucocorticoid therapy is an option for patients who have interstitial lung disease [",
"      <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/41\">",
"       41",
"      </a>",
"      ]. However, only limited observational data support any benefit of this treatment for patients with AT [",
"      <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/42\">",
"       42",
"      </a>",
"      ]. Other sparse data, including a randomized controlled trial with 13 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/99\">",
"       99",
"      </a>",
"      ] and a case series of 6 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/100\">",
"       100",
"      </a>",
"      ], indicate that short-term treatment with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"       betamethasone",
"      </a>",
"      may help improve ataxia in patients with AT. Regardless of whether glucocorticoid treatment is directed at interstitial lung disease or ataxia, the optimal dosing regimens and duration of therapy in AT are unknown, as is the safety of long-term treatment. Glucocorticoids can lead to a clinically significant increased risk of infection and insulin resistance in patients with AT and should therefore be used cautiously.",
"     </li>",
"     <li>",
"      In an eight-week open label study,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"       amantadine",
"      </a>",
"      treatment was associated with a modest improvement in motor symptoms (ataxia, involuntary movements, and parkinsonism) in 13 of 17 children with AT [",
"      <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/101\">",
"       101",
"      </a>",
"      ]. This finding requires confirmation in larger controlled studies.",
"     </li>",
"     <li>",
"      Chest clearance techniques and cough assist devices may be helpful for patients with bulbar and respiratory muscle weakness, and noninvasive ventilation is suggested for patients with chronic respiratory failure [",
"      <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Those with hypogammaglobulinemia or impaired specific antibody production, or who do not tolerate or fail therapy with antibiotics, should be given gamma globulin infusions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=see_link\">",
"       \"Medical management of immune deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children who have the capacity to produce antibodies should be immunized with pneumococcal and influenza vaccines.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The 13-valent pneumococcal conjugate vaccine (PCV13) should be given according to recommended schedules for high-risk children (",
"      <a class=\"graphic graphic_table graphicRef62519 \" href=\"UTD.htm?20/63/21501\">",
"       table 2",
"      </a>",
"      ). Dosing and schedules for PCV13 are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=see_link&amp;anchor=H13#H13\">",
"       \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\", section on 'Indications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The 23-valent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12422?source=see_link\">",
"       pneumococcal polysaccharide vaccine",
"      </a>",
"      (PPSV23) should be given to children who are age two years or older according to recommended schedules for high-risk children (",
"      <a class=\"graphic graphic_table graphicRef62519 \" href=\"UTD.htm?20/63/21501\">",
"       table 2",
"      </a>",
"      ). A detailed discussion of PPSV23 dosing and schedules is found elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13926?source=see_link&amp;anchor=H5#H5\">",
"       \"Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children\", section on 'Indications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      All children with AT and members of the household should be immunized with influenza vaccine annually. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link\">",
"       \"Seasonal influenza vaccination in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=see_link&amp;anchor=H7#H7\">",
"       \"Seasonal influenza vaccination in children\", section on 'Indications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Measuring postimmunization antibody levels has been proposed as a guide to determine the need for additional immunizations or gamma globulin replacement therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many children with AT have difficulty with coordination of swallowing and may aspirate foods, liquids, and oral secretions [",
"      <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/35\">",
"       35",
"      </a>",
"      ]. Swallowing should be formally evaluated in all patients. Children may also aspirate after gastroesophageal reflux, and the latter should also be investigated and treated as necessary. Gastrostomy tube feedings should be used to reduce the risk of aspiration and to maintain nutrition in symptomatic children.",
"     </li>",
"     <li>",
"      Pulmonary function can be measured with spirometry by making minor modifications to standard procedures [",
"      <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/44\">",
"       44",
"      </a>",
"      ]. Every attempt should be made to test pulmonary function in children with AT who develop chronic respiratory tract symptoms. Pulmonary function should also be part of the risk assessment for elective surgery for patients with AT who are age 10 years and older. Some experts advise regular assessment of lung function in all symptomatic and asymptomatic children with AT who are old enough to cooperate with testing, including yearly spirometry [",
"      <a class=\"abstract\" href=\"UTD.htm?22/60/23497/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Physical and occupational therapy are critical for maintaining the maximum possible level of function.",
"     </li>",
"     <li>",
"      Diagnostic tests involving x-rays and ionizing radiation should be avoided when possible to minimize the risk of somatic mutations and subsequent malignancy. However, such studies should not be withheld if they are required to provide optimal management.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11399656\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The defective gene in ataxia-telangiectasia (AT) maps to chromosome region 11q22.3 and is designated the AT mutated gene (ATM). The ATM gene product is expressed in all tissues in the body. ATM is involved in the detection of DNA damage, and plays an important role in cell cycle progression. Both the central and peripheral nervous systems are involved in AT. The central nervous system abnormalities are more severe and are primarily characterized by cerebellar atrophy with particular loss of Purkinje cells. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Genetics and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with AT who are homozygotes invariably suffer from progressive cerebellar ataxia, abnormal eye movements, other neurologic abnormalities, oculocutaneous telangiectasias, and immune deficiency. Associated features include pulmonary disease, an increased incidence of malignancy, radiation sensitivity, and diabetes mellitus caused by insulin resistance. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of AT is established by the presence of characteristic clinical findings (particularly progressive cerebellar ataxia) and identification of disabling mutations on both alleles for the ATM gene. It is supported by serum IgA at least two standard deviations below normal for age and by increased spontaneous and radiation-induced chromosome fragility in cultured cells. In the appropriate clinical setting, the finding of a serum alpha-fetoprotein at least two standard deviations above normal for age is diagnostic of the disorder. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AT can be difficult to distinguish clinically from other chronic ataxic syndromes. If ataxia develops early, AT may be misdiagnosed as an ataxic variety of cerebral palsy. When the onset is delayed, AT most often is mistaken for Friedreich ataxia. Several other diseases mirror the neurologic features of ataxia-telangiectasia, but result from defects in genes other than ATM. These include ataxia-ocular apraxia type 1, ataxia-ocular apraxia type 2, and ataxia-telangiectasia-like disorder. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AT is difficult to treat and has a poor prognosis because of its multisystem involvement. No specific treatment exists for the ataxic syndrome or the progressive cerebellar neurodegeneration. Many patients succumb to progressive pulmonary disease or to cancer, and the median age at death is approximately 25 years. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Current management strategies for patients with AT are based upon the treatment of disease manifestations. These strategies focus on the surveillance, prevention, and treatment of the major causes of morbidity related to AT, including infections, dysphagia, pulmonary disease, immune deficiency, and malignancy. (See",
"      <a class=\"local\" href=\"#H11401238\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5112307\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Howard Lederman, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/1\">",
"      Gatti RA, Berkel I, Boder E, et al. Localization of an ataxia-telangiectasia gene to chromosome 11q22-23. Nature 1988; 336:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/2\">",
"      Savitsky K, Bar-Shira A, Gilad S, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 1995; 268:1749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/3\">",
"      Ambrose M, Gatti RA. Pathogenesis of ataxia-telangiectasia: the next generation of ATM functions. Blood 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/4\">",
"      Khanna KK, Keating KE, Kozlov S, et al. ATM associates with and phosphorylates p53: mapping the region of interaction. Nat Genet 1998; 20:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/5\">",
"      Cortez D, Wang Y, Qin J, Elledge SJ. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 1999; 286:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/6\">",
"      Chen J. Ataxia telangiectasia-related protein is involved in the phosphorylation of BRCA1 following deoxyribonucleic acid damage. Cancer Res 2000; 60:5037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/7\">",
"      Swift M, Reitnauer PJ, Morrell D, Chase CL. Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med 1987; 316:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/8\">",
"      Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 1991; 325:1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/9\">",
"      Athma P, Rappaport R, Swift M. Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet 1996; 92:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/10\">",
"      Thompson D, Duedal S, Kirner J, et al. Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst 2005; 97:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/11\">",
"      Baskaran R, Wood LD, Whitaker LL, et al. Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature 1997; 387:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/12\">",
"      Wu X, Ranganathan V, Weisman DS, et al. ATM phosphorylation of Nijmegen breakage syndrome protein is required in a DNA damage response. Nature 2000; 405:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/13\">",
"      Yang DQ, Kastan MB. Participation of ATM in insulin signalling through phosphorylation of eIF-4E-binding protein 1. Nat Cell Biol 2000; 2:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/14\">",
"      Paroni G, Cernotta N, Dello Russo C, et al. PP2A regulates HDAC4 nuclear import. Mol Biol Cell 2008; 19:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/15\">",
"      Li J, Chen J, Ricupero CL, et al. Nuclear accumulation of HDAC4 in ATM deficiency promotes neurodegeneration in ataxia telangiectasia. Nat Med 2012; 18:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/16\">",
"      Kojis TL, Gatti RA, Sparkes RS. The cytogenetics of ataxia telangiectasia. Cancer Genet Cytogenet 1991; 56:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/17\">",
"      Canman CE, Lim DS. The role of ATM in DNA damage responses and cancer. Oncogene 1998; 17:3301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/18\">",
"      Suzuki K, Kodama S, Watanabe M. Recruitment of ATM protein to double strand DNA irradiated with ionizing radiation. J Biol Chem 1999; 274:25571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/19\">",
"      Barlow C, Hirotsune S, Paylor R, et al. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell 1996; 86:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/20\">",
"      Borghesani PR, Alt FW, Bottaro A, et al. Abnormal development of Purkinje cells and lymphocytes in Atm mutant mice. Proc Natl Acad Sci U S A 2000; 97:3336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/21\">",
"      Spring K, Ahangari F, Scott SP, et al. Mice heterozygous for mutation in Atm, the gene involved in ataxia-telangiectasia, have heightened susceptibility to cancer. Nat Genet 2002; 32:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/22\">",
"      Eaton JS, Lin ZP, Sartorelli AC, et al. Ataxia-telangiectasia mutated kinase regulates ribonucleotide reductase and mitochondrial homeostasis. J Clin Invest 2007; 117:2723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/23\">",
"      Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet 2005; 39:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/24\">",
"      Valentin-Vega YA, Maclean KH, Tait-Mulder J, et al. Mitochondrial dysfunction in ataxia-telangiectasia. Blood 2012; 119:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/25\">",
"      Paula-Barbosa MM, Ruela C, Tavares MA, et al. Cerebellar cortex ultrastructure in ataxia-telangiectasia. Ann Neurol 1983; 13:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/26\">",
"      Peterson RD, Cooper MD, Good RA. Lymphoid tissue abnormalities associated with ataxia-telangiectasia. Am J Med 1966; 41:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/27\">",
"      Swift M, Morrell D, Cromartie E, et al. The incidence and gene frequency of ataxia-telangiectasia in the United States. Am J Hum Genet 1986; 39:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/28\">",
"      Woods CG, Taylor AM. Ataxia telangiectasia in the British Isles: the clinical and laboratory features of 70 affected individuals. Q J Med 1992; 82:169.",
"     </a>",
"    </li>",
"    <li>",
"     Gatti R. Ataxia-telangiectasia. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK26468/ (Accessed on May 18, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/30\">",
"      Crawford TO. Ataxia telangiectasia. Semin Pediatr Neurol 1998; 5:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/31\">",
"      Perlman SL, Boder Deceased E, Sedgewick RP, Gatti RA. Ataxia-telangiectasia. Handb Clin Neurol 2012; 103:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/32\">",
"      Cabana MD, Crawford TO, Winkelstein JA, et al. Consequences of the delayed diagnosis of ataxia-telangiectasia. Pediatrics 1998; 102:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/33\">",
"      Lewis RF, Lederman HM, Crawford TO. Ocular motor abnormalities in ataxia telangiectasia. Ann Neurol 1999; 46:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/34\">",
"      Baloh RW, Yee RD, Boder E. Eye movements in ataxia-telangiectasia. Neurology 1978; 28:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/35\">",
"      Lefton-Greif MA, Crawford TO, Winkelstein JA, et al. Oropharyngeal dysphagia and aspiration in patients with ataxia-telangiectasia. J Pediatr 2000; 136:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/36\">",
"      Kwast O, Ignatowicz R. Progressive peripheral neuron degeneration in ataxia-telangiectasia: an electrophysiological study in children. Dev Med Child Neurol 1990; 32:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/37\">",
"      Taylor MJ, Logan WJ. Multimodal electrophysiological assessment of ataxia telangiectasia. Can J Neurol Sci 1983; 10:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/38\">",
"      Larnaout A, Belal S, Ben Hamida C, et al. Atypical ataxia telangiectasia with early childhood lower motor neuron degeneration: a clinicopathological observation in three siblings. J Neurol 1998; 245:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/39\">",
"      Nowak-Wegrzyn A, Crawford TO, Winkelstein JA, et al. Immunodeficiency and infections in ataxia-telangiectasia. J Pediatr 2004; 144:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/40\">",
"      Bott L, Lebreton J, Thumerelle C, et al. Lung disease in ataxia-telangiectasia. Acta Paediatr 2007; 96:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/41\">",
"      McGrath-Morrow SA, Gower WA, Rothblum-Oviatt C, et al. Evaluation and management of pulmonary disease in ataxia-telangiectasia. Pediatr Pulmonol 2010; 45:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/42\">",
"      Schroeder SA, Swift M, Sandoval C, Langston C. Interstitial lung disease in patients with ataxia-telangiectasia. Pediatr Pulmonol 2005; 39:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/43\">",
"      Crawford TO, Mandir AS, Lefton-Greif MA, et al. Quantitative neurologic assessment of ataxia-telangiectasia. Neurology 2000; 54:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/44\">",
"      McGrath-Morrow S, Lefton-Greif M, Rosquist K, et al. Pulmonary function in adolescents with ataxia telangiectasia. Pediatr Pulmonol 2008; 43:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/45\">",
"      Morrell D, Cromartie E, Swift M. Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. J Natl Cancer Inst 1986; 77:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/46\">",
"      Olsen JH, Hahnemann JM, B&oslash;rresen-Dale AL, et al. Cancer in patients with ataxia-telangiectasia and in their relatives in the nordic countries. J Natl Cancer Inst 2001; 93:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/47\">",
"      Morgan JL, Holcomb TM, Morrissey RW. Radiation reaction in ataxia telangiectasia. Am J Dis Child 1968; 116:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/48\">",
"      Iannuzzi CM, Atencio DP, Green S, et al. ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects. Int J Radiat Oncol Biol Phys 2002; 52:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/49\">",
"      Ho AY, Fan G, Atencio DP, et al. Possession of ATM sequence variants as predictor for late normal tissue responses in breast cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 2007; 69:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/50\">",
"      Waldmann TA, McIntire KR. Serum-alpha-fetoprotein levels in patients with ataxia-telangiectasia. Lancet 1972; 2:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/51\">",
"      Waldmann TA, Broder S, Goldman CK, et al. Disorders of B cells and helper T cells in the pathogenesis of the immunoglobulin deficiency of patients with ataxia telangiectasia. J Clin Invest 1983; 71:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/52\">",
"      Rivat-Peran L, Buriot D, Salier JP, et al. Immunoglobulins in ataxia-telangiectasia: evidence for IgG4 and IgA2 subclass deficiencies. Clin Immunol Immunopathol 1981; 20:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/53\">",
"      Roifman CM, Gelfand EW. Heterogeneity of the immunological deficiency in ataxia-telangiectasia: absence of a clinical-pathological correlation. Kroc Found Ser 1985; 19:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/54\">",
"      Sanal O, Ersoy F, Yel L, et al. Impaired IgG antibody production to pneumococcal polysaccharides in patients with ataxia-telangiectasia. J Clin Immunol 1999; 19:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/55\">",
"      Sadighi Akha AA, Humphrey RL, Winkelstein JA, et al. Oligo-/monoclonal gammopathy and hypergammaglobulinemia in ataxia-telangiectasia. A study of 90 patients. Medicine (Baltimore) 1999; 78:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/56\">",
"      Fiorilli M, Businco L, Pandolfi F, et al. Heterogeneity of immunological abnormalities in ataxia-telangiectasia. J Clin Immunol 1983; 3:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/57\">",
"      Giovannetti A, Mazzetta F, Caprini E, et al. Skewed T-cell receptor repertoire, decreased thymic output, and predominance of terminally differentiated T cells in ataxia telangiectasia. Blood 2002; 100:4082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/58\">",
"      Cawley LP, Schenken JR. Monoclonal hypergammaglobulinemia of the gamma M type in a nine-year-old girl with ataxia-telangiectasia. Am J Clin Pathol 1970; 54:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/59\">",
"      Taylor AM, Oxford JM, Metcalfe JA. Spontaneous cytogenetic abnormalities in lymphocytes from thirteen patients with ataxia telangiectasia. Int J Cancer 1981; 27:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/60\">",
"      McConville CM, Stankovic T, Byrd PJ, et al. Mutations associated with variant phenotypes in ataxia-telangiectasia. Am J Hum Genet 1996; 59:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/61\">",
"      Chun HH, Gatti RA. Ataxia-telangiectasia, an evolving phenotype. DNA Repair (Amst) 2004; 3:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/62\">",
"      D&ouml;rk T, Bendix-Waltes R, Wegner RD, Stumm M. Slow progression of ataxia-telangiectasia with double missense and in frame splice mutations. Am J Med Genet A 2004; 126A:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/63\">",
"      Alterman N, Fattal-Valevski A, Moyal L, et al. Ataxia-telangiectasia: mild neurological presentation despite null ATM mutation and severe cellular phenotype. Am J Med Genet A 2007; 143A:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/64\">",
"      Verhagen MM, Abdo WF, Willemsen MA, et al. Clinical spectrum of ataxia-telangiectasia in adulthood. Neurology 2009; 73:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/65\">",
"      Saunders-Pullman R, Raymond D, Stoessl AJ, et al. Variant ataxia-telangiectasia presenting as primary-appearing dystonia in Canadian Mennonites. Neurology 2012; 78:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/66\">",
"      Su Y, Swift M. Mortality rates among carriers of ataxia-telangiectasia mutant alleles. Ann Intern Med 2000; 133:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/67\">",
"      Olsen JH, Hahnemann JM, B&oslash;rresen-Dale AL, et al. Breast and other cancers in 1445 blood relatives of 75 Nordic patients with ataxia telangiectasia. Br J Cancer 2005; 93:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/68\">",
"      Renwick A, Thompson D, Seal S, et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 2006; 38:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/69\">",
"      Concannon P. ATM heterozygosity and cancer risk. Nat Genet 2002; 32:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/70\">",
"      FitzGerald MG, Bean JM, Hegde SR, et al. Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet 1997; 15:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/71\">",
"      D&ouml;rk T, Bendix R, Bremer M, et al. Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients. Cancer Res 2001; 61:7608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/72\">",
"      Gatti RA, Tward A, Concannon P. Cancer risk in ATM heterozygotes: a model of phenotypic and mechanistic differences between missense and truncating mutations. Mol Genet Metab 1999; 68:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/73\">",
"      Chenevix-Trench G, Spurdle AB, Gatei M, et al. Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst 2002; 94:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/74\">",
"      Teraoka SN, Malone KE, Doody DR, et al. Increased frequency of ATM mutations in breast carcinoma patients with early onset disease and positive family history. Cancer 2001; 92:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/75\">",
"      Stankovic T, Kidd AM, Sutcliffe A, et al. ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. Am J Hum Genet 1998; 62:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/76\">",
"      Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol 1999; 93:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/77\">",
"      Wu JT, Book L, Sudar K. Serum alpha fetoprotein (AFP) levels in normal infants. Pediatr Res 1981; 15:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/78\">",
"      Butch AW, Chun HH, Nahas SA, Gatti RA. Immunoassay to measure ataxia-telangiectasia mutated protein in cellular lysates. Clin Chem 2004; 50:2302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/79\">",
"      Chun HH, Sun X, Nahas SA, et al. Improved diagnostic testing for ataxia-telangiectasia by immunoblotting of nuclear lysates for ATM protein expression. Mol Genet Metab 2003; 80:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/80\">",
"      Maserati E, Ottolini A, Veggiotti P, et al. Ataxia-without-telangiectasia in two sisters with rearrangements of chromosomes 7 and 14. Clin Genet 1988; 34:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/81\">",
"      Aicardi J, Barbosa C, Andermann E, et al. Ataxia-ocular motor apraxia: a syndrome mimicking ataxia-telangiectasia. Ann Neurol 1988; 24:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/82\">",
"      Moreira MC, Barbot C, Tachi N, et al. The gene mutated in ataxia-ocular apraxia 1 encodes the new HIT/Zn-finger protein aprataxin. Nat Genet 2001; 29:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/83\">",
"      Date H, Onodera O, Tanaka H, et al. Early-onset ataxia with ocular motor apraxia and hypoalbuminemia is caused by mutations in a new HIT superfamily gene. Nat Genet 2001; 29:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/84\">",
"      Shimazaki H, Takiyama Y, Sakoe K, et al. Early-onset ataxia with ocular motor apraxia and hypoalbuminemia: the aprataxin gene mutations. Neurology 2002; 59:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/85\">",
"      Criscuolo C, Mancini P, Sacc&agrave; F, et al. Ataxia with oculomotor apraxia type 1 in Southern Italy: late onset and variable phenotype. Neurology 2004; 63:2173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/86\">",
"      Musumeci O, Naini A, Slonim AE, et al. Familial cerebellar ataxia with muscle coenzyme Q10 deficiency. Neurology 2001; 56:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/87\">",
"      Lamperti C, Naini A, Hirano M, et al. Cerebellar ataxia and coenzyme Q10 deficiency. Neurology 2003; 60:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/88\">",
"      Quinzii CM, Kattah AG, Naini A, et al. Coenzyme Q deficiency and cerebellar ataxia associated with an aprataxin mutation. Neurology 2005; 64:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/89\">",
"      Le Ber I, Dubourg O, Benoist JF, et al. Muscle coenzyme Q10 deficiencies in ataxia with oculomotor apraxia 1. Neurology 2007; 68:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/90\">",
"      N&eacute;meth AH, Bochukova E, Dunne E, et al. Autosomal recessive cerebellar ataxia with oculomotor apraxia (ataxia-telangiectasia-like syndrome) is linked to chromosome 9q34. Am J Hum Genet 2000; 67:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/91\">",
"      Moreira MC, Klur S, Watanabe M, et al. Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular apraxia 2. Nat Genet 2004; 36:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/92\">",
"      Duquette A, Roddier K, McNabb-Baltar J, et al. Mutations in senataxin responsible for Quebec cluster of ataxia with neuropathy. Ann Neurol 2005; 57:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/93\">",
"      Anheim M, Fleury MC, Franques J, et al. Clinical and molecular findings of ataxia with oculomotor apraxia type 2 in 4 families. Arch Neurol 2008; 65:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/94\">",
"      Anheim M, Monga B, Fleury M, et al. Ataxia with oculomotor apraxia type 2: clinical, biological and genotype/phenotype correlation study of a cohort of 90 patients. Brain 2009; 132:2688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/95\">",
"      Stewart GS, Maser RS, Stankovic T, et al. The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder. Cell 1999; 99:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/96\">",
"      Hernandez D, McConville CM, Stacey M, et al. A family showing no evidence of linkage between the ataxia telangiectasia gene and chromosome 11q22-23. J Med Genet 1993; 30:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/97\">",
"      Klein C, Wenning GK, Quinn NP, Marsden CD. Ataxia without telangiectasia masquerading as benign hereditary chorea. Mov Disord 1996; 11:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/98\">",
"      Crawford TO, Skolasky RL, Fernandez R, et al. Survival probability in ataxia telangiectasia. Arch Dis Child 2006; 91:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/99\">",
"      Zannolli R, Buoni S, Betti G, et al. A randomized trial of oral betamethasone to reduce ataxia symptoms in ataxia telangiectasia. Mov Disord 2012; 27:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/100\">",
"      Broccoletti T, Del Giudice E, Cirillo E, et al. Efficacy of very-low-dose betamethasone on neurological symptoms in ataxia-telangiectasia. Eur J Neurol 2011; 18:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/60/23497/abstract/101\">",
"      Nissenkorn A, Hassin-Baer S, Lerman SF, et al. Movement disorder in ataxia-telangiectasia: treatment with amantadine sulfate. J Child Neurol 2013; 28:155.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6233 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-6B4A64F196-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_60_23497=[""].join("\n");
var outline_f22_60_23497=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11399656\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENETICS AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Neurologic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Telangiectasias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Immune deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11399544\">",
"      Pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Laboratory abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Variant AT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Heterozygotes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Ataxia-ocular apraxia type 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Ataxia-ocular apraxia type 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Ataxia-telangiectasia-like disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11401238\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11399656\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5112307\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6233\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6233|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/62/41963\" title=\"table 1\">",
"      Diagnosis ataxia telangiectasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/63/21501\" title=\"table 2\">",
"      PCV and PPSV23 in high risk",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=related_link\">",
"      Characteristics of hereditary breast and ovarian cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15432?source=related_link\">",
"      Friedreich ataxia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/60/13258?source=related_link\">",
"      IgG subclass deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=related_link\">",
"      Medical management of immune deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37433?source=related_link\">",
"      Overview of the hereditary ataxias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13926?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=related_link\">",
"      Seasonal influenza vaccination in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_60_23498="Skin healing";
var content_f22_60_23498=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F58665&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F58665&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Skin healing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 447px; height: 669px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) In any wound, the initial gap is filled by blood that, upon clotting (formation of fibrin polymers), provides the initial stability to the wound. Plasma fibronectin, present in the clot, can be cross-linked with extracellular matrix components and fibrin to bridge the clot and tissues.",
"    <br>",
"     (B) The epidermal cells at the edges of the wound lose contact with other epithelial cells and with their basement membranes. At the same time, this loss of contact probably acts as a signal to trigger migration of the cells. Concurrently, basal epidermal cells adjacent to the migrating cells undergo division. The result of this coordinated migration and cell division is the gradual covering of the epidermal defect. The breakdown products from the injured cells, fibronectin, and lysosomal enzymes from leukocytes act as chemoattractants, resulting in an influx of macrophages, myofibroblasts, and fibroblasts. Simultaneously, endothelial cells proliferate and neovascularization begins. The phagocytic cells attracted to the wound remove part of the clot, while fibroblasts and myofibroblasts begin to deposit a new extracellular matrix.",
"     <br>",
"      (C) The concentric migration of epidermal cells, sustained by the mitotic activity of the trailing cells, fills the wound gap and displaces the remnants of the original clot (scab) toward the surface. Contact with other epidermal cells is the signal that stops migration. The trailing cells not only divide but also secrete basement membrane components. In this manner, the continuity of the epidermal basement membrane is restored. In a similar fashion, the concerted activity of fibroblasts, myofibroblasts, macrophages, and endothelial cells fills the dermal gap. At this point, the number of macrophages and myofibroblasts declines. Those capillaries that failed to establish a definitive flow pattern begin to be obliterated, and accumulation of the definitive extracellular matrix is initiated.",
"      <br>",
"       (D) The gap created by the wound has been repaired. The mitotic activity of the epidermal cells will restore the epidermal thickness. Most capillaries of the initial granulation tissue have been reabsorbed, and the dermal gap has been filled with a dense, almost avascular, extracellular matrix, composed predominantly of type I collagen.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"        Reproduced with permission from: Rubin E, Farber JL. Pathology, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 1999. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_60_23498=[""].join("\n");
var outline_f22_60_23498=null;
var title_f22_60_23499="Common Terminology Criteria for Adverse Events diarrhea";
var content_f22_60_23499=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F65649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F65649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    National Cancer Institute common terminology criteria for diarrhea",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Grade",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Description",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"       <td>",
"        Increase of less than four stools per day over baseline; mild increase in ostomy output compared to baseline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2",
"       </td>",
"       <td>",
"        Increase of four to six stools per day over baseline; moderate increase in ostomy output compared to baseline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3",
"       </td>",
"       <td>",
"        Increase of seven or more stools per day over baseline; incontinence; hospitalization indicated; severe increase in ostomy output compared to baseline; limiting self care activities of daily living",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4",
"       </td>",
"       <td>",
"        Life-threatening consequences; urgent intervention indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5",
"       </td>",
"       <td>",
"        Death",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     With permission from: Common Terminology Criteria for Adverse Events (CTCAE), version 4.03, June 2010, National Institutes of Health, National Cancer Institute, file://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_60_23499=[""].join("\n");
var outline_f22_60_23499=null;
var title_f22_60_23500="Approach fecal incontinence";
var content_f22_60_23500=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Approach to patients with fecal incontinence",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Obtain history",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Is the patient truly incontinent or does patient have frequency and urgency without incontinence?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        How long have symptoms been present?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Does the patient have minor or major incontinence?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Does the patient have urgency?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Could the patient be impacted?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Is there a background history of diarrhea? Could medications be contributing?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Does the patient have a prior history of vaginal delivery or anorectal surgery?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Does the patient have a history of prior pelvic irradiation?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Does the patient have a neurological disturbance?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Does the patient have diabetes mellitus?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Perform physical examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Examine the external anoderm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Test for an anal wink bilaterally",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inspect for prolapsing hemorrhoids or other obvious pathology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perform a digital examination while asking the patient to bear down and to squeeze",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Obtain specific anorectal testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flexible sigmoidoscopy in most patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Specific testing for patients with diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endorectal ultrasonography in patients with suspected sphincter disruption",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anorectal manometry in patients with structurally intact sphincters",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Specific treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medical therapy and/or biofeedback for motivated patients who have intact sphincters and manometry showing preserved rectal sensation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Surgical repair for patients with mechanical sphincter disruption in whom medical therapy is unsuccessful",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other sphincter restoring procedures in patients with major incontinence in centers with available expertise",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_60_23500=[""].join("\n");
var outline_f22_60_23500=null;
var title_f22_60_23501="Energy expenditure and weight";
var content_f22_60_23501=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F63172&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F63172&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Changes in energy expenditure minimize changes in weight",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 445px; height: 260px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Observed minus predicted energy expenditure in subjects studied during food-induced weight gain and diet-induced weight loss. Changes in weight were associated with parallel changes in total energy expenditure, thereby making further alterations in weight more difficult.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med 1995; 332:621.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_60_23501=[""].join("\n");
var outline_f22_60_23501=null;
var title_f22_60_23502="Adjusted MMSE norms";
var content_f22_60_23502=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F79818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F79818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mini-Mental State Examination norms by age, gender, and education level",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 351px; background-image: url(data:image/gif;base64,R0lGODlhiQFfAeYAAP///4CAgICzmYCZ//+AgAAAAEBAQMDAwAAz//8AAABmMyAgIKCgoDAwMPDw8EBm/0CMZsDZzXBwcP9AQODg4JCQkMDN/7CwsBAQEFBQUP/AwNDQ0GBgYP9QUBBwQKCz/xBA/zCDWaDGszBZ//8QENDZ/yBN//9wcHCN/+Ds5uDm/3CpjWCA/2CggFBz//+wsNDj2fDz//8wMP+goP8gIFCWc/+QkLDA/yB5TZC8pv/Q0LDQwP/w8PD28/9gYP/g4JCm/0BNgIBAQEBZTQAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAACJAV8BAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP09fb3+Pn6+/z9/v8AAwoc2GpDhQAMHAhywAChQoIQ5xWYWMCAoAYVCzSIyBEeAwAUJgK4UCADgAwFLnRcye6AhAIBAASAKRPmgQA4cR5gyTMcAwMFJNSMOTPAzZwGYvZc6g3ogQpBAbysUAgn06vXDjQI8LIAhZALDizwWlUp1rPRKGAssEAlAAZj/xd8LIu2rjirdvN2w6u3Lza+fgNPAyy4sDPChhMnQ6y4MTHGjiP/giy5Ew8NPwb9sEHghawZE3RkmnDCHOXKkTTwOKShQwICgn6QICEjQWlYBBJooKThtSACM0ybRW1pAokTmQklWA4bwIkENgCQSLBakA4CuzUQEN2a9OruE6IDAH4dwIsOE3zsJgQ6vHX0E3T/wA5g/m4eNia4P6Hfh2gfCUwAG3CCnOceADN01kEHol1zGnGPgBagZ4Pk1lx8u2GoWQIdAODaDy9w+FyHBPhAQHzBJTBdAjNwSEAHzQny3Amu2SAbCSfq1htsOwIQ3wknkAAADQQESQMAtdEwAf8AAZonom0+JkBDktMchVNSEGqiQ3wd/uZblBnqRkh8P3Do4WsE0JAAAPh1UBtsCcggiA1xEkgICUTmFh6L4+no2446JOBDbABowN90hX7ZpGurySBkfILUVmVOAWCZ5SWtxUlhn8255lltDQrSYm2exUfAqbA5agOdcC75W3xQDiIlqgmKmZsGPe7YY4EcviDprk1CGuWwxFrz4KWKzKCmeoRoACCzLXYQ4pGE8DCdkADQ2YEGLwwqpaG+NZntCRpES4hr2CXY27YYBoqjqdKR8IKvFr6gZqLSMrkkqyF2KKywxg6HLCQmVqfccsvJOJ0MoQ4C4G3jqWlmiwGG66r/vct1YDCbPlwL23O0ifkcDQDCpoNrAfKQ5L1RCilukByu9u+aDgo8cCq1JTfwsTeDEqirN/Pc89ChCE00ahtgJBZVoAQgBKpQRy311FRXbfXVWGet9dZcd+3112CHLfbYqK6XTAMYYOCSRU0/TfbbcMct99x012232AIuk5IBN7H9idFHV3PqMhhUYMAFC3BQtM2BdzO4MjNRtFPTjDe+zePKGJ6BW45QcFAFDwHAEGKAWx4N5sgwMFckQE20EQAbYFDRAoaUbvozqB+Tgd+QXOCAA2PtNNYGiNh+ezO5GwPXAcwTH8lYFGzA1lgmWVlpEANkr/323Hfv/ffghy/+//jkl2/++ehrb4E9J1Ztti+tT8R7I1AJdYBGWhXAgPUGYJ/+/wAMoAAHSEDvPWAA9tCO+4LRkJysrhEvURzsKjIUuggme8cbBUoWoBMAjOUCSrNgYDCYQUY4ACUYEMojKDKRmCStABh4oCCM1xESllARQDEARiqXCRpyxIY3RERKBCGB+XHChxEBYhANgYGYnNAklCuMEpdIiK5MhHOeQCJEBnDAAnrxi2AU4PqCoTksZpGHaLFAGNfIxjZ+b4yTMQkFDrc4KhInhoLggBE3oUU7LqUAk6tUHf0omQY04AIXSOEgCekYkkwEAxRYJBVj8IEpDsICJRgEJQfwgRjEov8ED/hAJlDwgF5QIAAViKQkg1gCECDgASY4RAkG8MpBjOCVCBhBLCyAAARSopYAqCQvVHdCCW6Cf0MQgDKXucwImM4ECMgkIh6AAGDeAAEuAIALEHADTXISACoYQDdVwIIHsCCT5HzAA1DgyUqqAAgqKEE5XSBKQljABev0ZAzm2UsAfNOf9fwAPtn5AXW6oJsfQIAJBqACYQJAnvkEgBpvUM5utmIBFeDARJimCWQyk5kQEIDlSqBQaGbzELwspT/7SUtfCsIEIAAAEBDwARWAYAQDAEFMLXBAFiCABQCgpisTilMWnFQQ13QBCrAJgFuiwKcIBGYtaemCAZjgnij/sCoCVLBUEDwAlAgA501zqktaerWaKmgFIBtggCKuchDKtBwvR2CBW1aymggYY0oF0dKVunSlNxhBTGfKAi7mNZjlrCU1PUlSE6AACJ4cxDazB02SApWXUVVpLUEQSwDEIAbhhOVhgUlNmXITAEud5WGXCkdVNBEmgoziIeLaOJKWsqUqsIBuI7tX06IAtQgAAiFUkEsE/JaWhc0eV42719Ii9QGu1OUgqLk9zEq0n1ItJTDFOoIP+HR9pA0rLdc33vGutLWp6IpWjHlGRNC2cdAM7GELUYKZ0hW0CrUANNNKCGpG86G5vIEFUADWGyS0lM61AAsErFNCzNQFFqBo/ww4O+B+uvKptdwmEO5JVZ6O9qoqKC1JIQzT85qYFQ6ogO8C4Ly/Ve69gSvBLUFQz0L4t5rr+wA0TVDjQRB1EPLNZTxdSU0EhxWct8ylNAehVaZ+gMj9fDIIllrKfbrSBOREwE0PS8toOlfHSjaxeQfzYpEyMhJL7TFxIAPjMzdCp5HNEptD+tE62/nOeM6znvfM5z7b2ZluJjMiIuDnQhv60Ig+dEgDrYqfvOUjElChi+HRZkaTYiYAMIBFNP1WdVTa0qLANKc5LVt3fBrUTatI2gyAgT1qoo/YODWqs8hC+T3Cc6h8CK5BVzs0mkPWs+YEBZhH7AO0mBHxe12ye/9NaTMHWxQOOEAkLxAAVTrCd8AD5Eh+FzwRtgPYz+4hJB0JSUlAjxDQ45+vyyEAOif63fD+KKArYwDFoYQDioRE/Qixb3XDg9DxDji8F40aLMlOJq5GRASrWAD2DgLWigG3YDjQAAZQ0K2O2GAHNW4Ub5tO4oG530Q+sgBJM6LWMUG5xy0H8sD8JCYH4FunA9fyM0M8MTXXy080zXOTd+Lmhmm3wIeu53mPI3IsTDgmgF4YgBP96R8lODkSWZH9GXvm4SZFzq/BEIxAEetZF8XWs6JRDIyC6WFvxNipkT8DyHDSaUfF2gdTawqWOu6lmLs0ds7ztoId753Quz7QDnj/9zp7HMMu9tWPSSlLFX4UQod6nY3eC6RTROmS8PfjR+F0yTOT8ryIHFs17fMjrnvz/3BAABaAAQ4cG+6o5wlUCnD2yjHvIRuQduz1cQGgYLT2QiwAVUJCk93fI3JJwcnb+Vi5idCuK0rZ+fADcIEinr4uPRCBAETQg0NE4PvfjwUMICCCTKwAAsGwvK3vTgi2pAQDY4nJSySAkgqInNX6a0wIFAABBYTgEAoQgAEYCxGgAIcXCfwnCNoXDIlXbK9nekJkABmQNkUBAPCHExVxPzFBEteHFTugADUAADWgADtgCAEIfoTQA9sHACkgACWYAi0AAS0AAwAQATUAARCQ/wOCsH0wIFIwEIM1UH6EIAI4qIMA0ANAaIAAsIJLWH49kANFCABECAE1UIIioAA4IAApsIAA8IMQsALdR2g7EIMluA2QUREkIQEVyBYOpIEA4IY4p4QCoISFEIBUSHk44AEAkAMKIAIp4AEhIAAeoIcC0ALt1ocAoAAeEIAp4H+FGIKDsAIKsAIjqIP7twItoIQJmIjo138rsAJ6WAMrIAA4oAApIIkeAAHjpwAsCIiC+H9zmIqMaIbNZxEHoHo0gRJG0RBuCIdBJ4cGOIcnKIKFqIgpQAhzuAMhoId8aIj9FwFPWAP7J1L+JwgwgIUrkAPdNwgekIVzqIoK0AI1qP+J6MeJ1yiOLMiC7VaKzrSJ/beHJAgAktiDCuBMkgh61XCGflOBDoBvMGQUNOGLhcGHKyCPCpADKQB+2ygIz0gIjXiJSxiOy5QCy5gDfEiN5QgAOwABi/h/g4CFyyQCBShSI8mJgsB/JSkIfxgCIpCJ7ViO7ziHziSTMhmR+EgNhJcYjYgDEVCKx0gIERCImegBC8mQAUiD1xgCOxABK3CNPCmJGCkIEdACSzmIhDCCAhAB2tcD3ciUSriImJiAg7gDyliANRABDYmFEZAC73iNZ5mHNhmX2pCTiSECpYgDQuiQ++d/NFgIV+iRGrmXIbCFdkiOKimYfSkISLiIHiD/UiKwiP3nmIMoiegHAyOYgEO5fzN5lO8ohaUYAjRYkzWpDIsnOg3BaysXd5KYl4WxATPBNg6AEUCBAaEzQx0IaoNYlILROmxzPxvhFKlpfH5xP7CJEQ2QOG/YeLcpnExBnAuBb2PRANGmnMyZGM4JAFARE7oYnNVZFwaBPwyBPxghQ3TZnfkQP9omAbLDQcxmnjuznO4ZGOUZnxwxn/QJEfZ5nwORn/oZEPzZn//wnwDaDwI6oPtQoAaaDwiaoPLAP8lHKRAaoRI6oRRaoRZ6oRiaoRq6oRzaoR76oSAaoiJ6oZMzDg4KopoWoimKog/aoSv6oS/qoi3qoTEqoyo6/6McWqMbqqM7Cp9/4aO2aQlI5ENDCqQyYaRBWglFKqRGuqTpQKRI6qSTIKWSoEVUWqVR2qRZqg5QyqReSglXCglWuqVKSqZTaqbn0KVl+qVnyqZYeglhKqZoGglxenRa6qZvCqZzKqdwuqd8uqZ6iqflwDyVQKiFWqKTYKiJiqiZx6iQoKiUAKmNagmSGgmV+giXiqmOyqCc2qlUtGsPMToJMQoG4RAL0RCjSgq5p0qiWpufoHinaqqlMDpK0aqjEG3FphC2Cm2nGaqo6qrbsGwAIJsaMQpJdxEZ8TqiEDvFR6zKCgq1hqxA8ayhwKwGQDvDmqyjIHKSk63TCm3ESv+b3lqs34BtwUMSJoESZtQJH0F8I1ESJzFEorAWGwiv6ioKE0Fs75qu8ioKwzMI6Bqv68oJuGpxXhGw9woKvplpgISw/foN0FOBFSgKLkETElt8TZNCFruxSHpyFZEBO3GxHcsI0rMA1FNBEzsKGqU4IhsKsakRyNmy4LBvMhsKPxEVNesJ0kNtHFtBoZABAVB2p9SzFCue+pOzoEB8kYS0BAudGoGLRIGx3bBw2BkVU1EKTrFvV5tqLIRKVit8WAtIWgu2y0pBRTG2HBUKKysIaBsK2RmvXisUW9sNHCdtbCEWZKGwW9EVX3G355a0zLOyfRsWf/uqW1F2DgAWeGv/baHwQUqjuIWrsBOhSpCbt59gcQ2QPwxQuYy7DSoHF2yxfJugFs7nFqArF6UwsacruppAuhrhPKtbCi+ER28RF6y7CUBhcrErCurJhoKwu54avMI7vMRbvMZ7vMibvMq7vMzbvM77vNAbvdI7vdRbvdZ7vdjLnKWaqruavfhwrONKrd5LD+0qEg57AdbTceMLDxUbte6reevrDjcrFEi7oPFrDFn7tWl7pPfbEns7uZzLnf0rDq7bFr9ru+05wAc6sgpMDvbbwM/wwBDcDBI8wctQwRa8GAycwd6AwRxsDB78wY+xwSI8lyRcwj+Kwu3AP25zN3TzPipsCizswnST/zcx3Aoh7AjJc8OnkMONsMP+cBk6sxmd8RmhMRoQY6fAAMTzoBqsgS6xMRu1kcStcCu88SV20gsvtDR/VwtMLA/GgRyFgDDN8RzRMR0Gcx3ZsR2Fgh4n8B3wIR7kARsGwizsoR/icTL6IR/0YR9skh/70R//ESADEhzmgR7ikSDnwSCxgDZqg3Gw1wtfLA8SMgGbwimCoCEaEhtm8iH9MiLjYSIowiQrEi0vEiPOYRs1ciM5git/4hs/EiRDUiR4giRSsiRN8slQEh9TIiWxsDd9UzT+40bdg16R0D40nMxUA8OosCVm4iUXIiabnMkJUCYdgi5psiZt8iZMIifZUv8nhjwIeHIqAUInwXErufIagTIo9VEoh7ImwLIkjIIkj0IzkgILhXM4yNk0w0zM2nNAlqBAyjzQqGLDqpApMrApFiIInmLLDTMqCVAqaDI4qsIq+lIhsJLEs3IqtbIb6PzK2PElTiItv6IoSzIzxAIwrmB5m/pqJ8wIlgQOk/wJyiIo7+MsNo0gveLL1XItc8Ih3OItNAAurTIn5GIug4Au5RLS7KIb7pIjsDEb8yID9XIv6+IZTcIvZoLSsVBGofbSixDT3zDTnlAwhoAwCeMcC9MwgvAwFSIxHUIx8CIuGBMz1dIxKvIxKlIbuzEyJQMAJ7McE6AyUsIy8eEyrgL/MxqT0jTzCqqTumCtCGLtDWSNCzkDEbsD2agw2Y6DysDwMxGxPM1za58TOrSawKXA2dxQ2YyEnphHCMJqrdhKCAKq2pfj2cHWQMr3COaqbf96CLXdRf483N5jzJCAzASd3MqtNcxsDdBTsicLv6WgRsRd3dsD0JUg0Mu93dwdNc3dCycEQ6XHCP1mtPtDnfhg28KZQzsECVQrPRaRskl6D+ptfPIKyYxQtx6UEiFE25GtDfW9e00kOhnwdR5LES6EEbTr3/kQ4LFnRQ/7c/+dDQ4ee17dxe1Q4ZsXAHJER+xHDxr+eLSrR0WTTJ53aDfpC1xk3cNt3GihbQhX4idu/2hSNwzUzeJuhN19YUiIlG+R3AqCxw8hDhGOBEOdC4GwEOT7MOQQcUqp9NWxoOT6wOQDQUwZ4HASHuUHuBRULhAYpVFk++OsIOUN/ld5sVZt9dqPit6vQObpLdw4bt0u3guvdSWcIN1A7m4zLnkpbgw3HudyXgzq1QBYznwEuOcnXuMJmmIr9oCGPg9uzrw+DAyRvryT/guVrryX7guZnryb3gudngqbZOb2tGSb1EmfFEqjpFK44GiPHWkYfg6hfgqt9EqdRV+0xOq3RE3S9QrW9Usq5VC4IGqbpuaBCul6Dm99LgqVlQj+pVJJpU2nJQgx8E3hNE7ldE7gVE4R5f9O8ARR9FQI9xRR+/QAkwVQfBVQA0VJBoVQCsVQDgVR7CRR4lRRrEDsmWbsbToPnTdwW14KjWVSiNBbfdVXg1BiM1VTY9VgPDUAPgVUQkVTueTwRwUASbVU2eRUUAUA2bVSVXVVSqVVy+VVYMVdZLVSZ7VVq/Caq9ZqsR4Qs64Ic1VXNNVl80XwLNVPTMZNgmVahUVNOZZYRsZYCvVYcSbtlBVNP3VdmSUIm9VZnxVa0AReKlVaM9VNqWVerLXydafveboUMZ8ItuVXubVbgtBbM/VbSyVcg0BcTrVSycVQS4UCzXVkFg9dudRfvaQ+/WRdHb9dNtVd38XxVS9eXJb/V+Y1ZqnQgMTm6C59FWGfCPF1S8ZcX7lkAfh1VftlY9WUSSQ1AgJGYNRkYIp1ZArGYDE1CA8WYSwwYVe1VAh0YT5VShrGYdjkYeAFYiJ2+yWW+POVCtE2bdUGCaAqCMUvwBAR+YggY1qmZoJwY4cFZjxmCD+GVEk2AkOGS0YmCCpw/UvGV9DkZFCGQFJGZZ7FAleWZVtGXp3/ZdA0Apnk+3MeauP2SEeeCMIqrAzOFMoPCACCg4SFhoeIACgIH4mOj5CRkpOUlY8GHAAZBRwYEpMXDg4LBQcAoaOlhQEBlq6vsLGyrwICs7e3ICAxuL2+v5YGrRgFAAEGlqQUhMoH/6yswsDS09SVAhC12drb3NoR1eDh4uMcDQwFyBLIlBUFn4Ptn87P0eP297cR3fv82Pj/AAM6OlCgIAMAC95JksCJEMNMhlgJnEgRWK2KGDNWYxDtgAFTkjYtYGVKJMlVrTSqXPnoIsuXMMUVnNlqZsGUgyTG3KnSJc+fPDkaGDpUITCdQJMC9Km0acYANguuk4bUqdVqTK9qxXeBmAEGBw5soFZ1q9lbWc+qpeaAQYMCGcCVXUuX0jV+eL/V3TuQQwEMcnHyHexIH959/ggrPvD2a7i5iiPDSitZLdSoU48KrszZmq3OdIUSNWD0F2TQqBFRTs260unWrVfDBkohrP9tsWQ3z4Yte/fOyzYzm9btO3Xv4i8vNyBa2tdr5JXvHs4L/Z6DAAswcBj7ax404tUrG56O+HN4e+2KdX92DPz594KOw791wUCBBRUCz99PSD7/V5cJw8pB0zz3X3H+HehaVOjkpuB8CT4oSW234VagexLOFmGGKhnIoXHYkEfdh/ZAtsEBDgDgwAHLABAWiYSNJ2I3icH4GHEMtXJOXAQ1YCN8G/4IIHEXNOgXYFB94oA62wnCQAD1SeAABwZwd0AGpKUYAAMVYJKikFoFCaZr4P0FAAZvbWCfKQ1gEECby9i3ACkYyHkKXAzFVVADpEA0plNi/inJafadU2QFxAD/sIE7d+Znn4sFtPLoJqyQAkCDDjQoaFOBbvrIae1YyidckLZCkKTFnArAo/axd+k6mnoKVKeyInLaoqRelt+ZC1xZwFiPqvpoOxkccEEmmsZa60602mihik9W8CUhrxGTH67cbfDWAgQGG+mq6mFXkJ6wCrfsS9LNqO4+esG2AVTrONDYX9MK4uG5yMm47r611NiafZr2CG5Y7NWD78Ge+UZQvG/xmYl37SEs8STNqrWwIFNiQEoD9RqD4cQgA1DxWRcD0E4rlKIU8sqHjLzVBu00gOI5Mr9FYE4fs4xPDyIIIEIPh0QgtNAYwQCBCLSYtwIEqQFckCkSEDNSRDnr/2xPCApAoEAIhyjgtdcYRaCAedYogMM3Pf93r9Xh7KBADQDUoMAOhng9NCE9+AxACgLQnUILELQAAwAR1AABBDnEJwIMtsAAeA1IEyLC4YkD0MPjY4scud495EA5AJNDUAPdLXgNQQppA+A4BCsArc8OgNMN29psY5W5AJkXYnoN7QqCgwcA5KCACCl4EIIAHgAvQAvXDA+AAh54ncLWy8M9yAoKrCB34livULotWQsSvtYrrAB8DSsIgIMCKWDvAQRGK7C38chzjfv70s9ede2224J7LV/7Rg2WB70U9GduIQCe8JintQh0rgZYAx/XVGe2FeQAaIPwAA4ACD8FtP+AcJkL3/M6+MG97e0a6/uGCLUWvLkBAHuMU8A3sNc71NCOf9IQ3gpeqIAcpGBoGBREAwkxve6JzIPZSEECcyA88DFNEDuAQPQmKL4N1kIEYrNFFkcoPghsURDFC4EISqfCJ7IQd99AIxqPWEPQ3BCHv5je2dZnQEJE4Hil80AQhei1wcFgazuIwAr+eDbsOVEQEWhBIJNHCLkJIAI964EGBZm56HkvfMnbwQ5CIDbeDdFsEUgBC//Iu9+x8ZSteSMcfSGC9eEgckTE2tYGVwgRbG0Qm/RaCFBnuhA+UYm6pKUgLhc9D9hCBNHT2jGThz2mwUBu4csj1tLYRxaCbn3/IRjcGteYyv2tciXYg+U3e6HKcVIkeXs05yzKqc52agViQ2GPPOdJz3ra8574zKc+98nPfvrznwANqEAHStB9giQ88BQQQOMpUIYG1KH/hGhEFTpRgkrUnxftZ0b5uVF9dtSj3tQfLNhpr5BSbaQmVdmQZEFSj8WipSSFaUpTE9OZ4uylNnUpSneK057ydKVADep8aupToZKpqJZoqU6NetSfJjWnSx1qTmWK1KYydRJKpapTn7pVq0q1q5TQqivEytWqerWsVx0UVJVamRe9wq1vPagr4GoJutZVrpWw611joVdK9HUSf41EYAWLV3ca9rCITaxiF8tYfFCgAgGQ/xbGnsSAjgEDZlv6UlsyK44TtWizlQVHhSbLWXFsNiWgtewvVnSbFKUWHJuVLLRK6xun+QgA87otNYIjiNyGYwPESIlvqxGV3qKjALqtBnDRsQDj2ie50iCITdh0XOiudl4YSNFwfYMKUhiLVJu4wEYAQIGC3Cku4QXHW75VJPQWQLy7LcWL2quJ94aDFNw5b33hOw3WnqMAFKBveqchsDUJ2L7QUQZUWrFg0ebIGN9qMFk8EeEKQxUSUikWhBn8LeXehxRxabCEweGXTIi4w9KQF3IXYGILQyceG47xRuzziRNf2BGLuoCNZTyNDATgSBTYcTV6xJgCPMnF4CgvgP9jPGJgZGxj10Gybx4iCBgzZFfgWJOVC4Dlo0Qlsoy6sji0HGYug2NRyFjwlrs8jRJXucxs9sXJ6gvmT4jZNyYJAIvucwBlUIMxAWAIgMvbKz9Pg0IlpgCh+7xkAjfgx/RatKGrQYoLvGXPhW70nwvSIklrGhg0KzIDPN2i3XwZAAwgBbeqQYH1LgC+qb7Pzaoh4Vivmhqt3hN3bD1ramjrLwTidThoTAhhVyNq90mJsRvL7GY7+9nQjra0p03talv72tjOtra3ze1ue/vb4A63uMdN7nKb+9zoTre6D8badbv7EILm77vfTYqGCKI+HNDJlbJ0iOscJMjipQCVmrT/bwPsakvvUhSVMtDrea/sUMRIUZEeban25gkR2TGZkSmApgBgAEn5LtSliAFg5P44Lg63ml8EbmRwxakYlBKXrd7bJo2HvBQOqEAG3lKT2y4qIbJN+coyxVzkgksQrIrUMxBR3rfUmBPPaDUGKjDnWNWHGNYVOsLakW9xbSBHF7AUsYyViXbgFWBjWVQDLnAACfy87d8KGAfY/nGtr+wtX2KIlORkKWPUG73NLQTNBmHpPVHgv616lSByjdz82p1thz8AA9CECAw0nCENf7yzlwsXxw+CAigvxMdVq/nSm/70qE+96lfP+ta7/vWwj73sZ0/72tv+9rjPve53z/veFPv+98APvvCHT/ziG//4yE8+awIBADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fifth percentile norms for the Mini-Mental State Examination (MMSE) were determined using a random population sample that incorporated the effects of age, gender, and education level, all factors that are felt to affect scores on the exam. In screening for dementia, the norms had a sensitivity and specificity of 85 and 89 percent, respectively.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission by Grigoletto, F, Zappala, G, Anderson, DW, Lebowitz, BD, Neurology 1999; 53:315.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_60_23502=[""].join("\n");
var outline_f22_60_23502=null;
var title_f22_60_23503="Loop of Henle segments";
var content_f22_60_23503=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F55088&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F55088&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anatomy of loop of henle segments",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 254px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Representation of the anatomic relationships of the outer cortical (left) and juxtamedullary (right) nephrons. Note that the outer cortical nephrons have no thin ascending limb, a short loop that turns around in the outer medulla, and a relatively long cortical aspect of the thick ascending limb. The latter segment is very short in juxtamedullary nephrons, which have glomeruli that are near the corticomedullary junction.",
"    <div class=\"footnotes\">",
"     PCT: proximal convoluted tubule (S1 and S2 segments); S3: last segment of the proximal tubule, which ends at the junction of the outer and inner stripes in the outer medulla; DLH: descending limb of the loop of Henle; tAL: thin ascending limb; TAL: medullary thick ascending limb; CAL: cortical thick ascending limb, which ends in the macula densa (MD, depicted as the shaded area adjacent to the glomerulus); DCT: distal convoluted tubule; CCT: cortical collecting tubule; and MCT: medullary collecting tubule.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Hogg, RJ, Kokko, JP, Rev Physiol Biochem Pharmacol 1979; 86:95, 1979.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_60_23503=[""].join("\n");
var outline_f22_60_23503=null;
